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In a transcatheter embolization procedure, an embolic agent is delivered 
locally via a microcatheter to obstruct blood flow in a blood vessel or vascular bed. 
These interventional radiology procedures are used to treat vascular 
abnormalities, hemorrhage, and neoplastic growths. Current embolization agents 
are plagued by toxicity and handling issues. An ideal embolic agent would be 
water-borne and not rely on in situ polymerization or precipitation from organic 
solvents for hardening. 
Complex coacervates represent a possible solution to these problems; they 
are an aqueous fluid morphology of associated polyelectrolytes that can be 
endowed with environmentally triggered solidification mechanisms. In this 
dissertation, the development of embolic coacervates (ECs) based upon an ionic 
strength driven setting mechanism is described. ECs are low-viscosity liquid 
coacervates in solutions of high ionic strength, but undergo a phase transition into 
a solid upon entering the low ionic strength environment of blood vessels. Early 
iterations were based upon the commercially available polycation protamine and 
an oligophosphate. These agents validated the ionic strength dependent setting 
mechanism and successfully occluded blood flow down to the capillary level in an 
acute transcatheter embolization of a rabbit kidney. Next, a synthetic polymer, 
poly(3-guanidinopropylmethacrylamide-co-methacrylamide), was developed to 
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replicate the structure of protamine while offering control over the mechanical 
properties of the embolic both before and after solidification. ECs made from this 
synthetic polymer demonstrated an increase in dynamic shear modulus of nearly 
4 orders of magnitude upon injection into physiological saline. In embolization of 
rabbit auricular arteries, these agents incited neutrophilic inflammation which 
began to subside at 2-4 weeks. At the endpoint of the study (4 weeks), occlusions 
remained stable and early signs of fibrous tissue deposition were observed. While 
longer-term tissue response studies are needed, embolic coacervates (ECs) 
represent a promising developmental embolic agent. 
In the final chapter, drug-releasing ECs were prepared with the 
antiangiogenic drug sunitinib malate. These ECs released 80% of their drug 
payload over the course of 14 days, displaying a linear zero order release profile. 
The results presented in this final chapter provide a framework for developing 
future embolics which prevent angiogenic revascularization resulting from post-
embolization ischemia.  
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In this dissertation, endovascular embolic agents with a novel water-borne 
composition and setting mechanism are presented. This approach was inspired by 
the adhesive of marine sandcastle worms. The natural adhesive is packaged and 
stored as sets of oppositely charged polyelectrolytes (PEs) which are condensed 
into complex fluids [1-4]. Within seconds of secretion from the adhesive gland, the 
fluid adhesive hardens into a solid–liquid foam [5]. The transition in morphology is 
largely driven by changes in ionic composition and concentrations when the fluid 
adhesive is exposed to seawater [6]. The in situ setting embolic coacervates (ECs) 
were designed to mimic the polyelectrolyte composition, condensed fluid form, and 
environmentally triggered setting mechanism of the natural sandcastle glue. In this 
chapter, the clinical context for therapeutic embolization is outlined with emphasis 
on the need for a new liquid embolization agent. Next, the phenomenon of complex 
coacervation is introduced as a solution to problems seen with current liquid 
embolic agents. Finally, the unique setting mechanism, which is based upon ionic 




1.2 Therapeutic Embolization 
 
Transcatheter embolization is an interventional radiology procedure that 
results in therapeutic occlusion of one or more blood vessels. Typically, a catheter 
is inserted into the femoral artery using the Seldinger technique. Then, under 
fluoroscopic guidance, the catheter is positioned and an embolization agent is 
delivered to produce a controlled, localized blockage. The first reported 
transcatheter embolization was performed in 1972 to stop bleeding from a 
duodenal hemorrhage using an autologous clot [7]. With the advancement of 
embolic agents and interventional radiology techniques, clinical uses for embolic 
agents have expanded from hemorrhages to include treatment of vascular 
abnormalities both in the central nervous system and in peripheral circulation [8, 
9]. Additionally, several types of tumors, both benign and cancerous, are treated 
by embolization. Generally, three factors are considered in choosing an 
embolization agent for a procedure: 1) the size of the vessel to be occluded; 2) the 
long-term viability of the target tissue; and 3) the desired duration of occlusion [8, 
10]. In large vessels, coils and gelatin sponges are most often used. For small 
vessel occlusion, liquid embolic agents or particles are most often used. However, 
there is great overlap between these scenarios. In many cases, more than one 
embolization agent may be used to create the desired surgical outcome. The 
following sections describe these agents in more detail, and mention the scenarios 





1.3 Current Embolization Agents 
1.3.1 Large Vessel Embolization Devices 
Large vessel embolization agents are mechanical devices that rely on 
native thrombus from the patient to stop blood flow. The most common device used 
in large vessels are embolization coils, which are most often constructed of either 
steel or platinum [8, 11]. These coils come in a variety of shapes and three-
dimensional (3D) configurations with sizes ranging from <1 millimeter up to several 
centimeters [8]. To increase their occlusive capability, thrombogenic polyester, 
nylon, or silk fibers are added to coils in a dense layer [11]. Coils are driven through 
the catheter and delivered by either forceful saline injection or a coil pusher wire. 
To prevent unwanted distal migration, coils should be oversized 20-30% compared 
to their target vessel. In situations requiring precision placement, detachable coils, 
which can be retrieved and repositioned, are used [11]. When a temporary 
occlusion of a large vessel is desired, gelatin sponge (Gelfoam), a material 
produced from porcine adipose tissue, is used. This material is sold in blocks which 
are formed by the surgeon into the desired geometry [10]. Gelfoam obstructs blood 
flow via a mixture of mechanical effects and providing a scaffold for native clot 
formation [12]. Typically, the sponge is cut into small 1-3 mm pieces or rolled into 
“torpedoes,” which can be injected into a large vessel. Placement of gelatin foam 
is much less precise than coils and produces a proximal occlusion [8].  Over 
several weeks, the Gelfoam material is resorbed and eventually the surrounding 




1.3.2 Particle Embolic Agents 
Particle embolic agents have sizes ranging from 100 μm to 1200 μm and 
are typically suspended in contrast and injected under fluoroscopic guidance [10]. 
These agents are carried in the downstream by blood and block vessels by 
physical entrapment. The occlusions are stabilized by native hemostatic clots and 
an ensuing inflammatory reaction [13]. These particle embolics can be divided into 
2 classes: nonspherical particles and microspheres. Nonspherical particles have 
been available since the 1970s and are generally made by mechanically 
processing sheets of material into small particles and diving them into size ranges 
using sieves [10, 13]. This process produces particles with irregular shapes and 
poorly defined size ranges [12]. Like Gelfoam ® sheets, gelatin sponge particles 
produced by this process also produce a temporary occlusion, recanalizing over 
several weeks. Irregularly shaped polyvinyl alcohol (PVA) particles are also 
produced by several manufacturers. Even though PVA is largely considered 
biocompatible, PVA particles adhere to the vessel wall, causing localized necrosis 
and a chronic, persistent foreign body reaction [12]. While PVA is considered a 
permanent embolic agent, instances of revascularization are seen [14]. The chief 
disadvantage of these irregular particles is their tendency to aggregate and cause 
occlusion proximal to the desired target [15]. While particles are still used in 
embolization procedures, embolic microspheres were developed in the 1990s to 
address some of their drawbacks. These systems come in well-defined size ranges 
from 40-1200 μm and have a well-controlled spherical shape [13]. Several 
iterations of PVA microspheres are approved by the FDA. Tris-acryl gelatin 
5 
 
microspheres (Embospheres ®) contain an acrylic polymer matrix which, in 
contrast to gelatin sponge particles, renders them nonresorbable. Histologically, 
microspheres of both types behave similarly to irregular PVA particles, causing 
focal angionecrosis and localized inflammation [12]. However, these microspheres 
are much more controllable, avoiding aggregation and off-target embolization.  
 
1.3.3 Cyanoacrylate Glues 
Alkyl cyanoacrylates are low-viscosity liquid resins that rapidly polymerize 
into hard adhesives on contact with anions. Historically, these were tissue 
adhesives that were often used off label as embolization agents [16]. In 2000, N-
Butyl-2 Cyanoacrylate (NBCA) (TruFill ®, DePuy Synthes, Inc.) received FDA 
approval for the presurgical embolization of cerebral arteriovenous malformations. 
In addition, NBCA is often used in other small vessel embolization scenarios [12]. 
NBCA occludes the blood vessel by immediately polymerizing into a hard, 
adhesive resin upon contact with anions present in blood. Recanalization is still 
seen in rare instances with NBCA [17]. To achieve distal penetration, NBCA is 
mixed with varying amounts of ethiodized oil, which retards polymerization. 
Ethiodized oil also provides some fluoroscopic visualization, but more often, 
micronized tantalum metal particles are used for contrast. For delivery, the catheter 
is flushed with a solution of 5% dextrose in water to prevent occlusion. Still, the 
catheter often becomes occluded after 1-2 injections [12]. Even worse, the catheter 
can become glued into the embolization site with NBCA [17, 18]. Misjudgment of 
the amount of NBCA or ethiodized oil needed for a procedure can result in 
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embolization spreading either proximal or distal to the desired site [12, 17]. 
Furthermore, upon injection, NBCA causes severe necrosis to surrounding tissue. 
Eventually this reaction progresses to a severe inflammatory response with 
perivascular inflammation and finally fibrosis [17, 19-21]. It is believed that this 
reaction largely results from localized hyperthermia from the exothermic heat of 
polymerization of cyanoacrylate monomers and from the byproducts of this 
reaction including formaldehyde and alkyl cyanoacetate [22]. 
 
1.3.4 Precipitating Embolic Agents 
Another approach used in liquid embolic agents has been to dissolve 
biocompatible polymers that are insoluble in water, such as ethylene vinyl alcohol 
(EVOH), in a water-miscible organic solvent, dimethyl sulfoxide (DMSO). This 
produces a low-viscosity solution that forms a polymer precipitate upon contact 
with aqueous media through the rapid diffusion of DMSO into the surrounding fluid 
[23]. In 2005, Onyx ® received the first FDA approval for this type of embolic agent. 
Like Trufill ®, Onyx ® is indicated for the presurgical embolization of brain 
arteriovenous malformations and contains micronized tantalum particles for 
fluoroscopic visualization [12]. Upon injection into blood, EVOH precipitates as a 
pliable, spongy material [23]. In comparison to NBCA, EVOH is nonadhesive and 
becomes less rigid, which allows for multiple injections. This also serves to reduce, 
but not eliminate risk of catheter entrapment compared to NBCA [12, 24]. On the 
other hand, DMSO is toxic and can cause vasospasm, tissue necrosis, and pain if 
injected too rapidly, which limits the delivery rate to 0.3 mL min-1, and it creates a 
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foul taste that can persist for days [25-28]. The slow delivery rate and rapid setting 
makes it difficult to control forward flow and penetration with EVOH [29, 30]. EVOH 
occludes vessels via a mixture of embolic agent and thrombus [21]. Vessel wall 
necrosis is seen in greater than 90% of AVMs embolized with Onyx, which incites 
perivascular infiltration and chronic inflammation dominated by foreign body giant 
cells [21, 31, 32]. Other embolic agents using this general mechanism are in early 
clinical usage. A copolymer of poly(lactide-co-glycolide) and poly(hydroxyethyl 
methacrylate) dissolved in DMSO is approved for clinical use in Europe. This 
system (PHIL ®) incorporates a triidophenol contrast agent into the polymer, 
elimating the use of tantalum particles for fluoroscopic guidance [33, 34]. While 
early experience suggests that PHIL ® may offer preferential handling 
characteristics in comparison to Onyx ® [33, 35, 36], this system retains the use 
of DMSO as a solvent which has been implicated in many of the adverse reactions 
to EVOH [25, 26]. 
 
1.4 Clinical Applications 
Transcatheter embolization is often applied by interventional radiologists in 
unique circumstances. Thus, a complete list of applications is difficult to compile. 
However, most clinical applications for embolic agents fall into 3 categories: (1) 
embolization of vascular abnormalities which have risks of complication (most 
often severe hemorrhage); (2) devascularization of undesirable neoplasmic 
growths; and (3) control of acute hemorrhage. Vascular abnormalities treated by 
embolization include dural arteriovenous fistulas, arteriovenous malformations 
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(AVMs) [37], arterial aneurysms [38], and varicoceles [39]. Tumors amenable to 
embolization include both benign tumors, such as uterine fibroids and 
hemangiomas [40], and malignant tumors like hepatocellular carcinoma [41]. 
Severe hemorrhage can result from a wide variety of causes, and embolization is 
used when bleeding cannot be managed with other techniques. Several of the 
most common clinical scenarios for embolization therapy are described in more 
detail in the following sections. 
 
1.4.1 Arteriovenous Malformations (AVMs) 
AVMs are congenital vascular abnormalities that can occur anywhere in the 
body; however, those within the central nervous system are the most problematic. 
AVMs consist of focal areas of dilated arteries and veins, referred to as a nidus. 
Within the nidus, no capillary bed exists, and blood flows directly from arterioles 
into the venous vasculature through at least one (but often several) arteriovenous 
fistulas, causing a lack of circulation to the surrounding parenchyma. The lack of 
fluid resistance from a capillary bed causes localized venous hypertension. 
Clinically, AVMs most often present as intracerebral hemorrhage. They carry a risk 
of catastrophic rupture, which can be fatal or have debilitating neurological effects 
[42]. AVM treatments are used to reduce the risk of hemorrhage and rupture [43]. 
These treatments are often guided by the Spetzler-Martin Scale, which grades 
AVMs based on size, location, and presence of deep venous drainage on a scale 
of 1-5, with 5 being the most severe [44]. With smaller AVMs, embolization may 
be used as a curative therapy [42]. In larger, Grade IV-V neural AVMs, 
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embolization is used to reduce blood flow to portions of the nidus prior to surgical 
resection or radiosurgery [43]. Peripheral AVMs are often left untreated, but may 
be treated on a case-by-case basis with embolization. Overwhelmingly, 
embolization of AVMs is performed using liquid embolic agents, typically either 
EVOH or NBCA [10, 12]. 
 
1.4.2 Aneurysms 
 Saccular aneurysms are thin-walled protrusions from arterial vessels, which 
are weakened by compromised vessel layers including tunica media and/or the 
internal elastic lamina [45]. Like AVMs, aneurysms can occur anywhere in the 
body, but intracranial saccular aneurysms are the most threatening due to their 
risk of catastrophic rupture and subsequent subarachnoid hemorrhages [46]. 
These intracranial aneurysms occur predominantly on the circle of Willis [47]. 
Peripheral aneurysms requiring treatment are most commonly found in the aorta 
[48], iliac artery [49], popliteal artery [50], and the visceral arteries [51]. While 
hemorrhage from catastrophic rupture can be life-threatening in large arteries, 
such as the aorta [48],  peripheral aneurysms are a source of downstream 
thromboemboli which can cause stroke and other ischemic events [52]. 
Embolization can be used to treat diagnosed nonruptured aneurysms or 
hemorrhage from ruptured aneurysms. Detachable coils are the most common 
endovascular therapy for aneurysms [12]. However, within this indication, there 
has been growing usage of liquid embolics in conjunction with coils [53-55]. In 





1.4.3 Hepatocellular Carcinoma and 
Malignant Hypervascular Tumors 
Hepatocellular Carcinoma (HCC) is a hypervascularized tumor that most 
often develops in patients with chronic fibrosis and/or cirrhosis [57]. Surgical 
resection or orthotopic liver transplantation, depending on liver function, are 
considered the best option for patients with early stage HCC (<3cm) [58, 59]. 
Unfortunately, HCC is typically undiagnosed until it has reached an intermediate 
to advanced stage where resection or transplantation are no longer viable options 
[59]. Even in cases where resection is done, 55% of patients exhibit tumor 
recurrence within 2 years, most of which are inoperable [58, 60]. In these advanced 
cases, transcatheter embolization has emerged as the primary mode of therapy 
[61, 62]. HCC is especially amenable to embolization because the tumor blood 
supply is primarily derived from the hepatic artery, while blood supply to healthy 
liver tissue is supplied through the portal vein [58]. While HCC is the most common 
target for embolotherapy, other hypervascularized tumors such as renal cell 
carcinoma, head and neck tumors, and colorectal carcinoma can also be treated 
by embolization. Embolization for tumors can be divided into conventional 
transarterial embolization (TAE) and transarterial chemoembolization (TACE). In 
TAE, an embolic agent is delivered alone to cause ischemic tumor necrosis [63]. 
TACE differs in that the embolic agent is co-administered with a chemotherapeutic 
agent, often doxorubicin [41]. For advanced HCC, TAE and TACE are the only 
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therapies to have repeatedly demonstrated a survival benefit compared to 
supportive care [58]. 
 
1.4.4 Uterine Fibroids 
 Uterine fibroids are neoplasms composed of smooth muscle cells and an 
associated extracellular matrix of connective tissue. These tumors originate from 
the muscular myometrium. While benign, growth of these fibroids can cause 
enlargement of the uterus, menorrhagia, and localized pressure on surrounding 
tissues including bowel and bladder. Generally, uterine fibroids are left untreated 
unless associated symptoms become unacceptable to the patient [64]. In these 
cases, treatment with nonsteroidal anti-inflammatory agents and hormonal 
androgens are an option. However, many patients require further intervention [64, 
65]. These interventions include surgical myomectomy, for women who wish to 
remain fertile, and hysterectomy. Percutaneous embolization is a less invasive 
option, but is not recommended for women who may want to have children [65]. 
Embolization of the fibroid causes ischemic infarction of the tumor, which results 
in gradual shrinkage and relief of associated symptoms. Treatment of a fibroid is 
considered permanent, although it does not prevent new fibroids from occurring 
[64]. Embolization is typically performed via the uterine artery with PVA particles, 






1.4.5 Control of Hemorrhage 
 Finally, percutaneous embolization can be used to control acute 
hemorrhage that is unmanageable with pharmacological or endoscopic 
interventions. Of these, traumatic and gastrointestinal (GI) hemorrhage have the 
highest incidence, but embolization is also used for pulmonary hemorrhage [67], 
severe obstetric bleeding [68], and epistaxis [69]. Trauma can destroy large 
vessels to extremities or to vital organs such as the liver, spleen, or kidneys 
causing life-threatening internal bleeding. Temporary occlusion is preferable in 
most trauma arterial embolization scenarios. Thus, in these cases, gelfoam blocks 
can be cut and crafted into cubes or torpedoes for large vessel occlusion [8]. 
However, in large vessels, such as the splenic artery, metallic coils are required. 
These coils may be used as scaffolding, in conjunction with other coils or gelfoam, 
particularly in patients with coagulopathy [8, 70]. Additionally, coils must be used 
in scenarios where a high degree of precision is required, such as near a major 
branch point [70]. Aside from trauma, GI hemorrhage can result from ulcers, 
vascular abnormalities, inflammatory diseases, and cancer [71, 72]. These lesions 
can include a variety of vessel sizes, and thus, the full spectrum of embolization 
agents including coils, particles, and liquid embolics may be used [71, 73, 74]. 
 
1.5 Developmental Liquid Embolic Agents 
As previously discussed, liquid embolization agents have various problems 
including poor tissue responses often resulting in necrosis, risk of catheter 
entrapment, and limited injection rates. An embolic agent that avoids both the 
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reactive monomers used in cyanoacrylate-based embolics and DMSO employed 
in precipitating systems could offer better handling characteristics and fewer 
adverse tissue reactions while improving distal penetration. The key design 
challenge in developing liquid embolics is to provide a low-viscosity formulation for 
delivery through long, narrow catheters while providing a setting mechanism for 
occlusion at the site of delivery. Many researchers have recognized this clinical 
need and sought to develop water-borne liquid embolic agents. The setting 
mechanism for most of these approaches fall into two distinct categories: single 
component systems that display inverse temperature sensitivity and two 
component systems that solidify upon mixing. However, both setting mechanisms 
have significant impediments to clinical use as liquid embolic agents for embolizing 
small vessels. 
The first approach has been to create embolic agents that solidify response 
to temperature changes. Most polymers have increased solubility at higher 
temperatures. However, certain hydrophobic polymers have a lower critical 
solution temperature (LCST) above which they become insoluble. At temperatures 
below the LCST, water forms a highly ordered structure around the hydrophobic 
moieties, which solvates the polymer [75]. This solvation involves the formation of 
enthalpically favorable hydrogen bonds. As the temperature of the solution is 
increased above the LCST, these hydrogen bonds are broken as solution entropy 
becomes dominant [75]. Stripped of their solvating water shell, the hydrophobic 
moieties coalesce and precipitate from solution.  
Inverse temperature sensitive polymers for use as embolic agents are 
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liquids at room temperature and have a lower critical solution temperature near 
37°C. Polymers containing N-isopropylacrylamide (NIPAM) are the most well-
characterized inverse thermosensitive polymers in the literature. This has resulted 
in the use of several NIPAM copolymers as experimental embolic agents [76-78]. 
Poloxomers are triblock copolymers of poly(ethylene oxide) (PEO) and 
polypropylene oxide (PPO), p(PEO-b-PPO-b-PEO), some of which exhibit inverse 
thermosensitivity [79]. Raymond et. al. developed temporary liquid embolic agents 
by forming a slurry with poloxomer-407 and nonionic contrast media.  Finally, 
Poursaid et. al. developed embolic agents made from silk-elastinlike protein 
polymers, which exhibit an irreversible temperature transition upon desolvation of 
elastinlike domains [80]. While many of these agents have demonstrated 
promising results in vivo, the temperature sensitive gelling mechanism represents 
a problem in a clinical scenario. In these settings, embolic agents must be 
delivered by small catheters, which are often 1 mm in diameter and up to 1.5 
meters long. Because of the high surface area to volume ratio within the catheter, 
these agents will reach 37°C almost instantaneously while still inside the catheter, 
causing premature setting. 
A second approach has been to create two component systems. 
Separately, each component is soluble in aqueous solution; when the two 
components are mixed, an insoluble gel is formed. The most prominent example 
of this type of system is a mixture comprised of calcium and alginate, which Becker 
et. al. first reported on in 2000 [81]. This system utilized a specialized dual lumen 
catheter to deliver the alginate and Ca2+ solutions to the embolization size 
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separately [81, 82]. Gore commercially acquired this system in 2006, but results 
from initiated phase I clinical trials have never been published [33]. In another 
system, Momeni et. al. used simple solutions of inorganic polyphosphate which 
were coacervated in situ with the divalent metal ions calcium, barium, and 
strontium. This system also requires a dual lumen delivery device that can 
generate mixing at the embolization site [83]. These systems present two main 
problems. If the diameter of the already small catheters is halved to create these 
dual lumen catheters, it will create a 16-fold increase in pressure (r4 dependence) 
to inject the embolic at the same rate, creating injectability problems. Second, the 
gelation of these systems is dependent upon complete mixing of the two 
components. Blood is more viscous than water and flows past the catheter tip in a 
laminar fashion. This will make it difficult to ensure good mixing upon delivery and 
effective setting. Finally, other two component systems have been designed that 
can be mixed prior to entering the catheter, such as the carboxymethyl chitosan- 
oxidized carboxymethyl cellulose system developed by Weng et. al. [84]. These 
systems have setting mechanisms that are slow and are decoupled from the 
process of entering the blood stream. These agents carry the risk of occluding the 
catheter, if injected too slowly, and crossing into venous circulation, if delivered too 
rapidly. 
 
1.6 Motivation For This Work 
 Complex coacervates have properties well suited to solving current 
problems with liquid embolic agents. This concentrated fluid morphology of 
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oppositely charged polyelectrolytes (PEs) has a totally water-borne composition, 
which can eliminate the intraarterial injection of organic solvents. Furthermore, 
polyelectrolyte complexes (PECs), including coacervates, have the ability to 
transform along a spectrum of morphologies, from liquid to solid, in response to 
external stimuli [85, 86]. That is, these materials can be designed with 
setting/hardening mechanisms based on solution conditions such as temperature, 
pH, presence of specific ions, or ionic strength [6, 85, 87]. In addition, coacervates 
have several properties which have led to their use as underwater adhesives and 
biomaterials: low water miscibility, low interfacial tension with water (facilitates 
spreading), ability to adhere to wet surfaces and dimensional stability upon 
injection into water [88]. In one example, these materials have been used for 
sealing iatrogenic fetal membrane defects [89]. Based upon these properties, 
embolic coacervates (ECs) were designed which transition from liquid to solid 
when injected into the blood vessel, in response to a decrease in ionic strength. 
This composition and setting mechanism are explained in more detail in the 
following sections. 
 
1.7 Adhesive of the Marine Sandcastle Worm 
 The inspiration behind the use of coacervates as adhesive biomaterials, 
and, ultimately this work, came from examining the undersea adhesive of the 
sandcastle worm (Phragmatopoma californica). Living in turbulent coastal 
environments, colonies of these worms build massive reef-like structures by gluing 
together grains of sand and mineral particles one at a time. This is accomplished 
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with a multipart adhesive that sets upon exposure to seawater [4, 88]. The 
sandcastle worm adhesive is largely composed of polyelectrolytic 
macromolecules, which are electrostatically condensed into secretory granules. 
The proteins within the glue are comprised of 40-50% ionizable amino acids, 
including lysine, histidine, and phosphorylated serine, which are segregated into 
different proteins. After deployment, the adhesive transitions from a liquid 
precursor to a solid-liquid foam in a two-step process, responding to external 
stimuli. First, with exposure to seawater (pH>8), there is an increase in pH from 
the internal environment (pH<6). This, coupled with a change in ionic composition, 
drastically decreases the solubility of the highly phosphorylated proteins, and 
induces a phase transition which produces the initial set of the glue. Slowly, over 
the course of a few hours, the glue is covalently crosslinked by the catechol 
oxidase enzyme. The final structure adhesive is a solid-liquid closed cell foam. The 
pores within this foam may contribute to the overall mechanical strength and 
toughness of the glue [4]. While, in the classical sense, coacervation is no longer 
thought to play a major role in this natural adhesive, the condensed polyelectrolyte 
packaging, setting mechanisms, and structure can still be mimicked by coacervate 
based systems for biomedical applications [4, 6, 85, 88]. 
 
1.8 Coacervates as Liquid Embolization Agents 
1.8.1 Coacervation 
When added together in solution, oppositely charged polyelectrolytes (PEs) 
can form a variety of associative morphologies [86]. These range from stable 
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colloidal suspensions, such as polymer-nucleic acid polyplexes used in gene 
delivery [90], to solid precipitates used in production of layer-by-layer films [91]. In 
between, within a narrow range of solution ionic strength, pH, temperature, PE 
charge densities, and charge stoichiometry, certain PEs can condense and 
undergo macroscopic liquid-liquid phase separation [92]. This phenomenon was 
first described by Bungenberg de Jong et. al. and named complex coacervation, 
which distinguishes it from liquid-liquid phase separation involving a single polymer 
[93, 94]. With coacervation, a PE rich, amorphous dense phase is formed and 
exists in equilibrium with a PE-depleted supernatant phase. Complex coacervation 
differs from formation of solid ionic gels in that the interactions between PE chains 
in a coacervate are fluid, allowing for rapid dynamic exchange; whereas, in an ionic 
gel, these interactions are kinetically arrested [95]. This fluidity results from a high 
content of water and small ions within the coacervate phase [86, 96, 97]. Overbeek 
and Voorn introduced a theory of complex coacervation in 1957, which combined 
electrostatic attractions using Debye-Hückel theory and mixing entropy described 
by Flory-Huggins theory [92, 95]. While Voorn-Overbeek theory and subsequent 
extensions provide adequate descriptions of  many systems, certain key 
observations remain unaddressed in this theory [95]. Growing evidence points to 
the importance of counterion release entropy as a dominating factor for association 
of oppositely charged PEs [92, 98]. Additionally, properties of the PEs involved 





1.8.2 Ionic Strength Dependent Morphologies 
of Associated Polyelectrolytes 
Perhaps the greatest determinant of phase behavior and properties of 
associated PE systems is ionic strength. In many PE systems, changing ionic 
strength causes the system to transition from a single-phase aqueous polymer 
solution in high salt, to a phase-separated, fluid complex coacervate in 
intermediate salt, and eventually transitioning into a solid at low ionic strength [86, 
101]. Wang et. al. demonstrated this ionic strength dependent morphology for 
polyelectrolyte complexes (PECs) of poly(styrene sulfonate) (PSS) and 
poly(diallyldimethylammonium) (PDADMA). Within the coacervate region of this 
system, a continuum of rheological properties was observed, as a nonlinear 
increase in viscosity occurred as the salt concentration was decreased. Ultimately, 
the system underwent a transition from a viscously dominated coacervate (fluid-
like) behavior to a precipitate, which displayed predominantly elastic character 
[86]. Moreover, these transitions were reversible with the addition or removal of 
salt, further demonstrating that salt concentration in phase separated PECs exists 
in an equilibrium between the dilute and concentrated phase [86, 97]. These 
changes were attributed to doping the PEC with monovalent ions. This salt doping 
process involves interrupting intrinsic ion pairs that form between oppositely 
charged PEs with small ions [102]. In a salt free system, no monovalent ions are 
present within the PEC, and 100% of the monomers on PEs are paired with a 
monomer of opposite charge. This results in interactions that are kinetically 
trapped, forming a solid [86, 95]. As salt is introduced to the system, the 
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monovalent ions begin to form ion pairs with a certain fraction of monomers, 
breaking up interactions between PEs. Since these interactions are in a state of 
dynamic equilibrium, the PEC gradually becomes more fluid as salt doping 
increases. The monovalent ions also bring in additional water molecules through 
increased osmotic pressure, further serving to plasticize the interactions between 
PEs [103]. Finally, once the system reaches a high enough ionic strength, all 
interactions between oppositely charged PEs are disrupted and the complex is 
solvated, forming a single-phase solution [86, 103].  
 
1.8.3 Control of PEC Morphological 
Changes in Response to Salt 
In engineering materials based upon these ionic strength dependent 
morphology changes in PE systems, understanding the design parameters that 
influence these phase transitions is key. As previously discussed, these PE 
systems can undergo two separate phase transitions with decreasing salt 
concentration, first from solution to coacervate (SC) and then from coacervate to 
precipitate (CP). Chollakup et. al. studied the effect of molecular weight (MW) on 
these transitions in a system of polyacrylic acid (PAA) and polyallylamine (PAH). 
In this study, it was concluded that MW of the larger PE greatly affected the salt 
concentration at which the CP phase transition occurred, with MW of the smaller 
PE component having a much smaller effect on this transition. However, as the 
salt concentration was increased, the MW of the smaller species ultimately 
determined the stability of the coacervate phase and the salt concentration at 
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which the SC phase transition was observed. With the size of the PAH fixed, 
increasing the molecular weight of the PAA from 1.8 kg/mol to 72 kg/mol increased 
this critical salt concentration from ~0.4 M to 3 M. In addition, these studies defined 
the role of charge stoichiometry in these phase transitions. At 1:1 charge ratio, the 
coacervate region was favored; that is, the critical salt concentration was lowered 
for the CP transition and increased for the SC transition in comparison to non-
stoichiometric ratios [101, 104]. In other studies, increased charge density (moles 
of charge per gram of polymer) has also been shown increase the critical salt 
concentration at which the SC phase transition occurs [105]. 
In addition to PE properties, the chemical properties of the ions in the 
solution cause them to interact differently with the PE species, thus affecting these 
transitions.  Ghostine et. al. investigated the incorporation of several anions (within 
the Hofmeister series) into complexes of PSS and PDADMA.  The investigation 
revealed that weakly hydrated chaotrophic anions, such as thiocyanate and iodide, 
were more efficiently included in the complex than well-hydrated kosmotrophs, 
such as acetate and fluoride. This effect was attributed to an increased loss in 
entropy when a more hydrated ion entered the complex [102]. Perry et. al. 
examined the effects of specific cations and anions on the SC phase transition in 
systems of PAA and PAH [106]. Divalent salts such as calcium chloride were much 
more effective at suppressing coacervation (SC transition), even when considering 
the overall ionic strength of the solution. In addition, a less-pronounced effect was 
noted with the Hofmeister series. Chaotrophic ions tended to decrease the critical 
salt concentration while kosmotrophs were observed to increase this concentration 
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(favoring phase separation) [106]. This is agreement with the work done by 
Ghostine and suggest that weakly hydrated ions tend to better interact with the 
PEs and suppress the formation of coacervates [102]. The effects of ion hydration 
on the PC transition would likely be similar. Weakly hydrated ions are more readily 
taken up in a PEC [107], thus disrupting interactions between PEs and increasing 
the salt concentration at which the PC transition occurs. 
 
1.8.4 Design of Embolic Coacervates 
with Novel Setting Mechanism 
The approach presented here capitalizes on the ionic strength dependent 
morphologies of associated PEs and is depicted in Figure 1.1. For these 
condensed PE systems, cationic guanidinium-containing polymers, both natural 
and synthetic, are used in conjunction with anionic oligophosphates. Embolic 
coacervates (ECs) of these strongly associating PEs are produced in high 
concentrations of sodium chloride (>1 M). While still a coacervate, these systems 
are just below the salt concentration for the SC phase transition. Resultantly, the 
coacervates contain a high concentration of Na+ and Cl- ions. These ions shield 
most of the interactions between the oppositely charged guanidium and phosphate 
sidechains, producing a low-viscosity injectable formulation. When injected into a 
lower-ionic strength environment, such as a blood vessel (~150 mM), Na+ and Cl- 
ions are free to diffuse across in and out of the coacervate. As the salt 
concentration within the polyelectrolyte complex decreases, water becomes 
excluded, and the electrostatic interactions become less shielded by monovalent 
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ions, allowing increased intrinsic ion pairing between the PEs. This produces a 
phase transition of the complex from a liquid coacervate to a solid ionic gel, thereby 
occluding the blood vessel. To some degree, this setting mechanism mirrors that 
of precipitating liquid embolics but eliminates the used of organic solvents in favor 
of a totally water-borne composition. In precipitating systems, EVOH is dissolved 
in DMSO, a “good” solvent. Upon injection into the blood vessel, the DMSO 
diffuses away leaving copolymer in an aqueous environment (i.e., a “poor” solvent) 
and producing a precipitate. The high salt and water content of ECs are a “good” 
solvent for the PEs, while the low ionic strength environment represents a “poor” 
solvent and causes precipitation of the PEC. 
 
1.8.5 Embolic Coacervates as Drug Delivery Vehicles 
In the final chapter of this dissertation, ECs were loaded with an 
antiangiogenic drug, sunitinib malate, to prevent aggressive revascularization of 
embolized tissues, especially hypervascular tumors. This work is driven by another 
property of coacervates: the ability to encapsulate and release a wide variety of 
substrates. Coacervate-based encapsulation allows for the concentration and 
protection of proteins, nucleic acids, small molecules, and lipophilic compounds in 
a purely aqueous environment [108]. This loading can be facilitated by electrostatic 
interactions, preferential partitioning based upon differential solubility between 
coacervate and aqueous phases, and specific interactions between PEs and 
encapsulated solutes. Coacervates have been used in food science to encapsulate 
lipophilic compounds such as omega-3 fatty acids, polyphenolic compounds, and 
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various peptides [109]. More recently, the partitioning of aromatic dyes into 
coacervates made from adenosine triphosphate and PDADMA have revealed that 
these molecules are enriched 9-7200 fold in the coacervate phase [110]. This 
preferential partitioning into the coacervate phase is driven by differential solubility, 
electrostatic interactions, and aromatic π-π interactions [110, 111]. Naturally, 
these properties have facilitated their use as drug delivery vehicles, both for 
biomacromolecules and small molecules. Coacervates are often used for small 
molecules to overcome poor solubility of hydrophobic drugs [108]. Coacervate-
based PECs for small molecule drug delivery have included chitosan/o-
carboxymethyl chitosan for doxorubicin [112], gelatin coacervates for salbutamol 





Figure 1.1. Ionic strength dependent setting mechanism. Embolic coacervates are 
formulated into a low-viscosity injectable form in high concentrations of sodium 
chloride. Upon injection, monovalent ions diffuse away causing the complex to 
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COACERVATES OF PROTAMINE AND HEXAMETAPHOSPHATE AS 
TRANSCATHETER LIQUID EMBOLIC AGENTS 
 
3.1 Abstract 
 Transcatheter embolization is used to treat a variety of vascular 
abnormalities. Small vessels are most often embolized with liquid embolic agents; 
however, these agents incite adverse tissue reactions. Coacervates represent a 
new type of liquid embolization agent that is water-borne and holds promise for 
eliminating some of these reactions. Here, embolic coacervates of protamine and 
hexametaphosphate are described. In a rabbit auricular artery embolization, these 
agents demonstrated a benign inflammatory response, leaving the vessel wall 
structure intact and causing little impact on the surrounding tissue. 
 
3.2 Introduction 
 Liquid embolic agents are delivered via microcatheter to permanently stop 
blood flow in small vessels [1].  Most commonly, these agents are used in 
presurgical devascularization of arteriovenous malformations, but are also used in 
tumor embolization, treatment of aneurysms, renal ablations, and control of 
hemorrhage [1, 2]. Clinical liquid embolic agents include Onyx ®, a solution of 
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ethylene-vinyl alcohol copolymer dissolved in DMSO which sets in situ as the 
solvent diffuses away [3], and Trufill ®, a cyanoacrylate glue which polymerizes 
upon contact with anions in blood [4]. The problems with these agents are well 
documented. The DMSO employed in precipitating systems is toxic, limiting 
injection rates, and can cause vasospasm and tissue necrosis [5, 6]. 
Cyanoacrylate monomers polymerize rapidly and exothermically, making them 
difficult to control and causing localized hyperthermia. This rapid polymerization 
can be retarded by dispersing NBCA in ethiodized oil. However, misjudging the 
amount for a procedure can cause the embolus to spread proximal or distal to the 
desired area [4, 7]. Moreover, if the embolic agent refluxes, the catheter can 
become permanently glued into the embolization site [8, 9]. In addition, forward 
flow and distal penetration are difficult to achieve with Onyx [10]. 
 Many researchers have identified these problems with clinically used 
embolic agents and sought to develop new liquid embolic agents. However, these 
approaches, which generally fall into two distinct categories, are clinically 
infeasible for transcatheter embolization of small blood vessels. The first approach 
has been to create embolic agents that solidify in response to temperature 
changes. These systems are liquids at room temperature and have a lower critical 
solution temperature near 37°C, which causes them to harden. Examples of this 
approach include poloxomers [11], N-isopropylacrylamide copolymers [12], and 
silk-elastinlike protein polymers [13]. However, because liquid embolic agents 
must be delivered by small catheters (<1 mm OD), up to 1.5 m in length, the 
embolic agents will reach 37°C before reaching the end of the catheter, causing 
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them to set and obstruct the catheter prior to entering the blood vessel. A second 
approach has been to create two component systems. Separately, each 
component is soluble in aqueous solution, but phase separate into insoluble gels 
upon mixing. Examples of this type of system include mixtures of calcium and 
alginate [14], inorganic polyphosphate and divalent metal ions [15], and modified 
chitosan [16]. Because of their rapid gelation, these systems must be delivered by 
dual-lumen catheters, which can create high injection pressures due to their small 
diameters. In addition, generating the turbulence necessary to achieve complete 
mixing of the components at the delivery site presents an even larger challenge. 
Our lab has developed endovascular embolic agents based upon a novel 
ionic strength triggered setting mechanism [17]. This setting mechanism, inspired 
by the adhesive of the marine sandcastle worm, is made possible by 
interchangeable fluid morphologies of associated oppositely charged 
polyelectrolytes [18-23]. Under high ionic strength conditions, a liquid complex 
coacervate state occurs, as monovalent ions disrupt interactions between charges 
on the polyions. At low ionic strength, these same polyelectrolytes form a solid 
precipitate. When the liquid form at high ionic strength is placed into a solution of 
physiological ionic strength, diffusion of the monovalent ions out of the liquid 
coacervate phase allows the polyions to associate more strongly, leading to 
gelation of the coacervate. An embolic coacervate (EC) with protamine, a cationic 
polypeptide isolated from salmon sperm, and phytic acid, a cyclic organic 
polyphosphate, validated this ionic strength dependent setting mechanism. 
Furthermore, these ECs were injectable through clinically used 1 mm diameter, 3 
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F microcatheters, and in an acute transcatheter embolization of a rabbit kidney, 
demonstrated complete devascularization of the kidney without crossing into 
venous circulation [17]. Like other developmental embolics, this aqueous system 
eliminates use of organic solvents and rapidly polymerizing components. However, 
unlike the systems described above, the embolic coacervates are a single 
component system that can be injected through a single lumen catheter and does 
not begin to solidify until exiting the catheter. 
Here, we present the rheological properties of ECs made from protamine 
(PRT) and sodium hexametaphosphate (MP), an inorganic polyphosphate. 
Building upon the successful acute rabbit kidney embolization, we sought to 
examine the subchronic vascular response to the ECs by embolizing the central 
auricular artery in the rabbit ear. This model is advantageous because it allows for 
simple access to the target blood vessel and easy visualization of the embolic 
agent. It has been used previously as a fast-flow vessel model to study a range of 
prospective embolic agents, including particle and liquid embolics [11, 15, 24-27]. 
Additionally, as a thermal regulation center, the ear has numerous arteriovenous 
anastomoses [28, 29], which allow for collateral blood flow and help contain 
ischemia resulting from embolization [25]. Finally, as protamine is known to 
reverse heparin, in vitro release experiments were performed to measure 





3.3 Results and Discussion 
3.3.1 Production of Embolic Coacervates 
Commercial MP is a mixture of inorganic phosphate oligomers, both cyclic 
and linear, usually containing 10-20 phosphorous atoms per chain [30-33]. In their 
fully ionized form, cyclic inorganic polyphosphates have the formula (PnO3n)n-, 
while the linear form is comprised of (PnO3n+1)n+2-. The structures of these forms 
are depicted in Figure 3.1. Regardless of the whether the polyphosphate is linear 
or cyclic, each phosphorus atom will have one strongly ionized hydrogen, which 
has a pKa of around 4.5 or less [30, 34]. The weakly acidic end groups of linear 
polyphosphates are usually dissociated between pH 4.5 and 9.5 [30, 35]. Overall 
this contribution to charge density is relatively small, so 1 charge per phosphorous 
atom was assumed at pH 7.2, the pH used in preparation of ECs. For PRT, all 21 
arginine residues were assumed to be fully protonated, based upon published pKa 
values [36]. Except for the ratio experiments, coacervates of PRT and MP were 
prepared at a 1:1 charge ratio with PRT concentration fixed at 50 mg/mL. To 
maximize yield, complexes were formed in 800 mM NaCl. The supernatant was 
then removed, and 5 M NaCl was added to raise the [NaCl] in the coacervate to 
1200 mM, forming a clear, fluid coacervate. 30 wt% micronized tantalum oxide 
(TaO) was added as a fluoroscopic contrast agent to produce the EC. 
 
3.3.2 PRT-MP Rheological Characterization 
 The viscosity of PRT-MP coacervates as a function of NaCl concentration 
was measured at 0.02 s-1. As with coacervates of PRT and phytic acid (IP6) [17], 
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viscosity increased sharply as NaCl concentration was lowered below 600 mM 
(Figure 3.2). At 150 mM, the viscosity of ECs with MP was increased 2.5-fold over 
those made with IP6 (100 Pa·s vs. 40 Pa·s). With the TaO contrast agent, the low 
shear viscosity increased to 450 Pa·s. The higher viscosities of PRT-MP 
coacervates, both with and without contrast, indicate a much more stable final 
form. While no overpenetration was observed in the acute rabbit kidney 
embolization [17], this further reduces the risk of the embolic agent crossing into 
venous circulation. The higher viscosity of PRT-MP coacervates compared with 
PRT-IP6 is likely a result of the increased charge valency of MP. 
 From calculations using Poiseuille’s Law, shear rates of up to 500 s-1 may 
be generated within the catheter during delivery of the embolic agent. To predict 
this flow behavior, the viscosity of PRT-MP ECs in 1200 mM NaCl was determined 
from 0.01-500 s-1 (Figure 3.3). PRT-MP displayed a small amount of shear thinning 
up to 1 s-1, but was mostly Newtonian, having a viscosity of 2.8 Pa·s from 1 to 500 
s-1. With 30 wt.% TaO, the EC had a low shear viscosity of 15 Pa·s, but quickly 
shear thinned to a viscosity of 4.5 Pa·s by a shear rate of 10 s-1. From 10 s-1 to 500 
s-1, it behaved like a Newtonian fluid. This translates to a calculated injection 
pressure of roughly 5-6 MPa in a 3 F, 135 cm catheter, which is higher than PRT-
IP6, but within the limitations of modern 3 F embolic catheters (up to 8 MPa). 
 
3.3.3 Structure of Set Embolic Coacervate 
 The structure of the set PRT-MP EC was also examined using microscopy. 
Here, EC was made with 0.1% FITC labeled PRT (no TaO) and were injected into 
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150 mM NaCl. Upon delivery into physiological ionic strength, salt rapidly diffuses 
out of the EC and a phase transition occurs within seconds; the clear, flowing 
coacervate hardens and forms an opaque, porous gel (Figure 3.4). The lower salt 
concentration, in addition to increasing the strength of interactions between PEs, 
results in a decrease in equilibrium water content within the complex. The 
formation of pores likely results from the trapping of this excess water upon setting. 
This mechanism also explains the closed cell nature of the pores and their 
exclusion of FITC-PRT, as seen in the confocal image (Figure 3.4 B). The pore 
size varies greatly, depending on the thickness and geometry in which the EC is 
applied. Here, the EC was injected onto a glass slide, forming a droplet 
approximately 3 mm in diameter, and pores could be observed ranging in diameter 
from 10 to 500 μm. The formation of closed pores upon phase transition has been 
noted in other PEC systems [37]. Additionally, in response to changes in pH and 
the presence of Ca2+ ions, the natural adhesive of the sandcastle worm forms a 
closed pore network which may contribute to its adhesive and mechanical 
properties [38]. The contribution of the porous structure to the mechanical 
properties of ECs is a topic of future investigation. 
 
3.3.4 Embolization of Rabbit Auricular Artery 
 Previously, ECs were successfully utilized for acute transcatheter 
embolization of a rabbit kidney. Here, the longer-term tissue response to ECs was 
evaluated using the rabbit auricular artery model. Using aseptic technique, PRT-
MP EC was made with 30 wt% TaO as a fluoroscopic contrast agent. Lidocaine 
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was applied to numb the ear prior to the procedure. A small intravascular catheter 
was used to gain access to the artery, and approximately 25 μL of EC was 
subsequently injected. Immediate inhibition of blood flow was evident by gross 
observation because of the thinness of the rabbit ear.  Setting of the coacervate 
occurred within a few seconds after distal penetration of 2-3 cm. No further 
migration or fragmentation was observed. The animal was monitored afterward, 
and no signs of distress to the animal or tissue necrosis were seen. At 28 days, 
the rabbit was euthanized and the ears were fixed, sectioned, and embedded for 
histological examination. 
 
3.3.5 Histological Evaluation 
 Histological sections were stained with H&E, Masson’s Trichrome, and 
Verhoeff-Van Gieson elastin stain. Examination showed complete occlusion of the 
central auricular artery and penetration into several smaller arterioles. Vessel 
occlusions include both mechanical obstruction of the vessel with the embolic 
material and associated native thrombus. The EC remained confined to the artery 
lumen with no extravasation into surrounding tissues. Arterial vessels are lined by 
a single layer of endothelial cells, also known as the tunica intima. Surrounding 
this layer is the internal elastic lamina, which responds to blood volume changes 
within the artery, and a layer of smooth muscle (tunica media). The much less 
prominent external elastic lamina separates the tunica media from the tunica 
adventitia, a layer of connective tissue that surrounds the vessel. In the embolized 
vessels, arterial structure remained essentially intact (Figure 3.5 A). Tunica media 
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and tunica adventitia were not affected by the embolization (Figure 3.5 B). Only 
focal disruptions are seen in the internal elastic lamina (Figure 3.5 C). While the 
single-layer tunica intima cannot be identified in the sections, no signs of 
angionecrosis or cytotoxicity were seen. By 28 days, the EC was separated into 
smaller globules, and tissue ingrowth can be seen (Figure 3.5 A). This tissue 
ingrowth includes macrophages, fibroblasts, and sporadic foreign body giant cells. 
Using Masson’s trichrome, extensive collagen deposition by fibroblasts was seen 
throughout the artery (Figure 3.5 D). In sections with complete filling of the artery, 
no signs of revascularization were seen. In one section, only partially filled with 
EC, formation of endothelial tubules was seen in the associated thrombus (Figure 
3.6). These tubules are signs of angiogenesis, which can occur long before clinical 
recanalization. In this case, none of the tubules contained RBCs, indicating a lack 
of patency, but over time some blood flow would be restored to the embolized area. 
The long-term stability of the embolus in fully filled sections will need to be 
investigated in future animal experiments. The process of fibrosis would likely 
encapsulate and sequester the EC, which may serve to stabilize the occlusion. 
 The tissue response seen in this pilot experiment is strikingly different from 
published studies with other clinical embolic agents. Polyvinyl alcohol particles 
cause a severe inflammatory response within the lumen of the embolized vessel. 
This response contains large numbers of foreign body giant cells and often leads 
to necrosis of the vessel wall [39]. The precipitating embolic agent Onyx ® causes 
angionecrosis to the vessel wall, likely due to DMSO injection. It also incites 
chronic perivascular inflammation and results in complete destruction of the elastic 
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lamina in most cases [40, 41]. Cyanoacrylate glues produce a similar reaction, with 
necrosis and destruction of vessel structure [42-45]. The toxicity of cyanoacrylate 
embolics is thought to be a result of localized hyperthermia, caused by exothermic 
polymerization and of the production of toxic side products, including formaldehyde 
[45]. In contrast, no angionecrosis was seen with the EC. As with all foreign 
materials, the EC incited an associated inflammatory response. In this case, 
infiltration of macrophages and small numbers of FBGCs were seen. However, this 
response was relatively mild and had little effect on the vessel wall. In a clinical 
scenario, this could better preserve the function of surrounding tissue, which would 
be significant in neural applications. This difference in response is likely a result of 
the water-borne nature of embolic coacervates. The ionic strength dependent 
setting mechanism eliminates the use of organic solvents and in situ 
polymerization, which are significant sources of the toxicity seen with other liquid 
embolic agents. 
 
3.3.6 Effect of Charge Ratio on Protamine Release 
  The primary medical indication for PRT is reversal of the anticoagulant 
effects of heparin [46]. This interaction is caused by formation of a protamine-
heparin complex, which prevents heparin binding and activation of antithrombin 
and the subsequent inactivation of several coagulation factors [47, 48]. In some 
transcatheter embolization procedures, heparin is given to prevent thrombus 
formation caused by blood-material interactions with the catheter. In a heparinized 
patient, if some PRT is released from the embolic complex upon injection, it could 
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cause an undesired systemic procoagulant state. Upon injection of ECs, this 
release is possible because these polymer-rich polyelectrolyte complexes exist in 
a state of equilibrium with the dilute phase. In systems with high salt concentration, 
a significant amount of polymer remains in the supernatant phase at equilibrium 
[20]. As the EC is injected into PE free media, this could result in release of PRT 
and, less significantly, MP into the blood stream. Conversely, as ionic strength 
decreases and the coacervate transitions to a more solid morphology, the PEs 
become kinetically trapped, leaving almost no polymer in the supernatant [20, 49]. 
Because of this shift in equilibrium, the overall release of PRT should be limited. 
Still, the amount of PRT released from the EC upon delivery into serum was 
investigated. Additionally, as a way of minimizing this PRT escape upon injection, 
we also evaluated ECs formed with a non-stoichiometric 1:2 ratio of guanidinium 
to phosphate. 
To measure PRT release, known amounts of EC made with FITC-labeled 
PRT were injected into vials containing serum. PRT release was then determined 
by fluorescently quantifying the amount of PRT in the serum at given timepoints. 
To evaluate the effect of changing the guanidinium to phosphate ratio, release was 
first measured at 1 h. Increasing the charge ratio from 1:1 to 1:2 (guan:phos) 
resulted in a three-fold drop in the amount of PRT released, from 0.28% to 0.09% 
(Figure 3.7 A). To confirm that decreased PRT release in serum from the 1:2 EC 
was not a function of altered flow behavior, rheological properties were evaluated 
(Figure 3.7 B). ECs with 1:2 charge ratio displayed less shear thinning than 1:1 
ECs over the first couple of decades measured, then settled to roughly the same 
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viscosity from 10 s-1 to 500 s-1. Viscosity is a measure of the cohesive forces within 
a fluid. If this difference in release were related to the low shear viscosity, the 1:1 
formulation would be expected to exhibit lower release. According to our 
experimental data, the opposite is true, confirming that increasing the phosphate 
content of the coacervate was responsible for the decrease in release. Additionally, 
in terms of flow behavior, this small difference at low shear rates would be 
indistinguishable in the high shear environment of catheter flow, making a 1:2 
formulation desirable for future studies. 
Despite their high concentration of PEs, coacervates retain a large amount 
of water. This water in the coacervate phase can harbor free, unassociated PE 
within the complex, resulting in non-stochiometric complexes (which are still 
charge neutral because of monovalent ions) [37]. Likewise, increasing the amount 
of oligophosphate (MP) during formation of the EC would cause some free MP to 
be trapped within the complex. It is hypothesized that this free NaMP accounts for 
the decrease in PRT release. Because PRT complexation with MP is an 
equilibrium process, when the ECs are injected into physiological saline, which 
contains no free PRT, some might become disassociated from MP and be 
released. By introducing free MP into the coacervate, an internal reservoir of free 
polyvalent guanidinium binding sites is created, increasing the chance that this 
disassociated PRT is bound before escaping the EC. Simultaneously, because of 
the decrease in ionic strength with setting, complexation between polyelectrolytes 
becomes more favored, further helping to kinetically trap the PRT within the 
embolus and limit release. 
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3.3.7 Protamine Release Timecourse 
Based upon the decreased release of the 1:2 EC, the release profile was 
investigated out to 3 days (72 h) for this formulation (Figure 3.8). Very little PRT 
was released initially, only 0.02% after 5 min and 0.03% after 10 min. The release 
of PRT continued out to 3 days, where still only 0.85% had escaped. If it is 
assumed that release scales linearly with volume, injection of 1 mL of EC would 
release 0.2 mg within 5 min, 0.7 mg within 1 h, and 3.6 mg within 1 day. These 
values are a small fraction of the maximum endovascular PRT dosage of 50 mg. 
For reference, 1 mg of PRT is given to reverse the effects of 100 units of heparin. 
Considering that heparin is unusually infused at a rate of ~1250 units per hour, and 
that more heparin could be administered to counteract any PRT release, this short-
term PRT escape is insignificant. Additionally, the short half-life of PRT (< 5 min) 
is sufficient to prevent any long-term accumulation of PRT in the blood stream. 
While this release data is encouraging, more studies are necessary, as in vivo 
release is likely to depend heavily upon surface area. Before clinical translation, 




 Embolic coacervates produced from protamine and hexametaphosphate 
were more viscous than those made from protamine and phytate, resulting from 
the increased valency of the oligophosphate. Injection of these ECs into 
physiological saline produced a closed cell structure of aqueous pores. The tissue 
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response to the PRT-MP EC was evaluated in a rabbit auricular artery. At 28 days, 
the occlusion remained stable and a mild inflammatory response, resulting in 
tissue ingrowth and fibrosis of the embolic material was observed. While more in-
depth studies of this response are needed, this preliminary experiment supports 
our hypothesis that water-based ECs will create a more biologically inert embolic 
agent. Finally, protamine release was investigated as a function of coacervate 
charge ratio. A 1:2 ratio of guanidinium to phosphate produced lower overall 
release than 1:1 without significantly changing the rheological properties. Future 
studies with ECs will be done using a 1:2 ratio. 
 
3.5 Materials and Methods 
3.5.1 Reagents 
 USP grade Protamine sulfate (PRT; cat #102752) and sodium chloride 
(cat#102892) were purchased from MP Biomedical. Tantalum oxide powder, 
particle size <20μm (TaO; cat #204536), and sodium hexametaphosphate (MP; 
cat#305553) were obtained from Sigma. Fluorescein isothiocyanate was 
purchased from Fisher Scientific (FITC; cat #119250010).  Sterile sheep serum 
was obtained from Hemostat Laboratories, Inc. Solutions were made in ultrapure, 
double deionized water. 
 
3.5.2 Production of Coacervates 
PRT and MP were dissolved in 800 mM NaCl at 60 mg/mL and 105 mg/mL, 
respectively and adjusted to pH 7.2.  When applicable, 35 mg/mL (30 wt% of the 
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final coacervate) of TaO powder was added to the PRT solution.  The two solutions 
were mixed at a volume ratio of 4:1, resulting in a 1:1 charge ratio. Liquid-liquid 
phase separation occurred immediately, and the mixture was allowed to settle for 
12 h at 22°C. The supernatant was discarded, and 5 M NaCl was added to raise 
the coacervate NaCl concentration to 1200 mM, assuming that the NaCl 
concentration in the dilute and concentrated phases was equal [50]. This material 
was loaded into syringes and used as the in situ setting embolic coacervate (EC). 
In ratio experiments, the general procedure for producing the coacervate 
remained the same. However, coacervates were also produced with an arginine 
to phosphate ratio of 1:2. In this case, the overall batch concentration of PRT 
remained fixed at 50 mg/mL. However, MP concentration was increased from 21 
mg/mL at the 1:1 charge ratio to 42 mg/mL at the 1:2 charge ratio. As a result of 
the increased MP, the 1:2 ratio contained 200 mM excess sodium phosphate, and 
therefore, 200 mM sodium chloride was subtracted to correct the overall ionic 
strength. 
 
3.5.3 Production of Fluorescently Labeled Protamine 
FITC-PRT was produced using procedures from Nagai et. al. [51]. In 0.1 M 
borate buffer (pH=9), PRT was dissolved at 25 mg/mL. FITC was added (1.2 molar 
equivalents) along with a few drops of ethanol. The solution was reacted for 4 h at 
20°C. Afterward, the pH was adjusted to 7.5 using boric acid and kept at 4°C 
overnight. The product was purified by dialysis and lyophilized. Thin layer 
chromatography was used to confirm covalent labeling. When labeling was 
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The flow behavior of embolic coacervates was characterized at 37°C on a 
strain controlled rheometer (AR 2000ex, TA Instruments). A 20 mm diameter, 4o 
cone geometry was used with a solvent trap to prevent evaporation. Shear rate 
was stepped from 0.01 s-1 to 500 s-1 at 10 points per decade. Viscosities at various 
salt concentrations were compared at a shear rate of 0.02 s-1. 
 
3.5.5 Confocal Microscopy 
PRT-MP ECs were prepared with 0.1% FITC-PRT. 10 μL of the clear, 
homogenous coacervate was pipetted onto a glass slide in 150 mM NaCl and 
equilibrated for 24 h. Confocal images were taken with a Nikon A1R microscope 
using a 488 nm laser. 
 
3.5.6 Rabbit Auricular Artery Embolization 
The subchronic tissue response to the EC was evaluated in a rabbit 
auricular artery model. All animal studies were carried out in accordance with the 
University of Utah Institutional Animal Care and Use Committee (IACUC) 
guidelines and approved protocols. Prior to the procedure, the rabbit was weighed 
and the ear was shaved and cleaned with 70% isopropyl alcohol. A local anesthetic 
cream (EMLA) was applied topically 1 h prior to the procedure. A sterile 24 gauge 
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intravascular catheter (BD Medical) was advanced into the central artery of the 
ear. The central needle was withdrawn from the catheter, and before embolizing, 
the catheter was flushed with saline to confirm arterial positioning. The embolic 
agent was injected to fill 1-2 cm of the artery (~ 25 μL) as the catheter was slowly 
retracted. After 2 min, the catheter was completely removed, and pressure on the 
artery was maintained. Embolization was verified visually. At 28 days, euthanasia 
was performed by first sedating the rabbit with ketamine/xylazine (IM) followed by 
intravenous injection of euthanasia solution (VetOne). During necropsy, ear tissue 
was harvested and fixed with 10% buffered formalin. After 1 week, the ears were 
cut into small sections (~4 cm2) for embedding and staining. Sections were 
embedded in paraffin before staining with hematoxylin and eosin, Verhoeff-Van 
Gieson elastin stain, and Masson’s trichrome stain. 
 
3.5.7 Protamine Escape Experiments 
 Coacervates for the PRT escape experiments were produced as described 
previously, but with 10% FITC-PRT. All samples for this experiment contained the 
TaO contrast agent. To measure release of PRT in serum, 25 μL of coacervate 
was injected into 500 μL of sheep serum in an Eppendorf tube. At designated 
timepoints, the serum was mixed and completely removed. Separate samples 
were used for each timepoint (n=4). Finally, 200 μL of serum was combined with 
80 μL of borate buffer and loaded into a 96 well plate. PRT in serum was 
determined by measuring fluorescence intensity (Ex. 495 nm; Em. 531 nm) and 
comparing with known PRT standards. Percent PRT release was calculated based 
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upon total concentration of PRT in the coacervate phase (800 mg/mL), determined 
from total volume of coacervate produced and amount of FITC-PRT leftover in the 





Figure 3.1. Simplified structures of hexametaphosphate (MP). The commercially 
available product contains mixtures of cyclic and linear inorganic polyphosphate 








Figure 3.3. Rheological flow curves for PRT-MP ECs (n=3). 
  



















Figure 3.4. Microscopy images of FITC-labeled PRT-MP EC injected into 150 mM 




Figure 3.5. Histological response to PRT-MP (+TaO) at 28 days. (A) H&E stain 
showing embolized auricular artery. (B) Higher magnification of H&E stain showing 
tissue ingrowth. Tunica media (TM) and tunica adventitia (TA) are fully intact. (C) 
Elastin stain showing mostly intact inner elastic lamina (black); some focal 
disruption of the internal elastic lamina is seen (star). (D) Trichrome stain of 
embolized vessel demonstrating fibrosis throughout. One nidus of fibrosis is 





Figure 3.6. Neovascularization within embolized vessel. (A) An incompletely filled 
section of the auricular artery showing formation of endothelialized tubules. (B) 
Higher magnification of tubules (stars). No RBCs are seen, suggesting these 
tubules are not patent. Scale bars: 50 μm.  
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Figure 3.7. Properties of ECs (+TaO) with varying +/- charge ratios. (A) 1 h release 











































Figure 3.8. Cumulative release profile for ECs at 1:2 ratio (n=4). 
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ELECTRON BEAM STERILIZATION OF PROTAMINE-
HEXAMETAPHOSPHATE EMBOLIC COACERVATES 
 
4.1 Abstract 
 Electron beam sterilization is a commonly used radiation sterilization 
method. It is commonly used as an alternative to gamma radiation as it causes 
less damage to proteins and polymers. Here, the effects of e-beam sterilization on 
the material properties of embolic coacervates made from protamine sulfate and 
sodium hexametaphosphate are evaluated. Based upon observational, 
rheological, and spectroscopic data, electron beam sterilization did not change the 
chemical or physical properties of the embolic coacervates. 
 
4.2 Introduction 
Radiation sterilization methods are among the most commonly used for the 
sterilization of single-use medical devices. Their high usage stems from the simple 
and direct correlation of radiation dosage with killing of microbes, which makes 
validation relatively simple[1]. Of these methods, gamma radiation is most-widely 
used, followed by electron beam (e-beam). In e-beam sterilization, an electron 
80 
 
accelerator is used to generate a focused beam of electrons from electricity[2, 3]. 
The primary advantage of e-beam in comparison with gamma radiation is less 
oxidation of the product due to reduced processing times. Its main disadvantage 
is its short penetration depth, which is only a few centimeters in high density 
products[1, 3]. Because of this, packaging must be carefully considered to ensure 
adequate microbial kill. 
In situ setting coacervates of sodium hexametaphosphate (MP) and 
protamine sulfate (PRT) (described previously in Chapter 3) are currently under 
preclinical investigation as liquid embolic agents. Sterilization of proteins and 
polymers can cause unwanted crosslinking or degradation, necessitating 
expensive aseptic production methods. In this study, e-beam sterilization was 
evaluated as a postpackaging sterilization method. PRT-MP coacervates were 
produced with and without tantalum oxide (TaO), an X-ray contrast agent for 
endovascular embolization. These embolic coacervates were sterilized using a 15 
kGy dose of e-beam radiation. Material properties of the sterilized samples were 
compared to unsterilized material from the same batch. 
 
4.3 Results and Discussion 
4.3.1 Observation of Setting Behavior 
Solidification of the salt-setting coacervates was observed by dispensing 
them into physiological saline. PRT-MP coacervates, in both e-beam sterilized and 
control groups, became cloudy and hardened immediately after immersion into 
saline, forming a foamy structure. Vigorous shaking did not disturb the set 
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coacervates. The sterilized and control TaO-containing material also solidified and 
formed identical structures upon addition into saline (Figure 4.1). No color change 
or separation was observed in any of the samples. These observations, while only 
quantitative, established that there are no gross differences in sample behavior 
within the two groups. The following sections describe further investigations into 
the strength of the electrostatic interactions between PRT and MP, in addition to 
evaluation of chemical changes as a result of the sterilization process. 
 
4.3.2 Flow Behavior 
Trans-catheter delivery is essential for a liquid embolic agent. The pressure 
required to deliver the embolic at any flow rate can be reliably predicted from flow 
curves (viscosity vs. shear rate) and the physical dimensions of the catheter[4]. 
Flow curves of the embolic coacervates were evaluated at 37°C. PRT-MP 
exhibited a viscosity of 3.7 Pa·s at 0.1 s-1 and shear-thinned to 2.7 Pa·s at 500 s-1 
(Figure 4.2A). TaO containing embolic coacervates exhibited much more shear-
thinning, going from 15 Pa·s to 3.4 Pa·s over the same range (Figure 4.2B). More 
importantly, no significant differences were observed between e-beam sterilized 
and control samples, indicating that the e-beam sterilized samples will be 
deliverable under the same conditions as control samples. Additionally, these 
results suggest that no significant degradation or crosslinking occurred within the 
sterilized samples, as these changes would have likely modified the molecular 




4.3.3 31P Nuclear Magnetic Resonance 
(NMR) Spectroscopy 
MP is a mixture of cyclic and linear inorganic polyphosphates of varying 
lengths, which contain hydrolysable pyrophosphate bonds. 31P NMR can be used 
to resolve internal and terminal phosphate groups of inorganic polyphosphates in 
addition to their degradation product, ortho-phosphate[5]. An example spectra 
depicting these phosphate groups and their associated NMR peaks is shown in 
Figure 4.3A. This technique was used to evaluate MP degradation resulting from 
the sterilization process in coacervates with and without TaO. PRT-MP embolic 
coacervates did not degrade significantly in either group, with an orthophosphate 
peak present but too small to integrate (Figure 4.3B).  TaO containing embolic 
coacervates (Figure 4.3C) had slightly more degraded phosphate in the 
unsterilized form (4.8%) than in the sterilized form (3.2%). This difference is likely 
insignificant, especially given that it is unlikely that radiation would recondense 
degraded inorganic phosphate. Notably, the amount of degraded phosphate within 
these NMR spectra is greater than coacervates without TaO. However, it is clear 
from these results (and the proceeding flow curves) that e-beam sterilization does 
not accelerate the degradation of MP in the coacervate form. 
 
4.3.4 Attenuated Total Reflectance 
Infrared (ATR-IR) Spectroscopy 
While NMR was used to monitor the degradation of MP in response to e-
beam radiation, PRT contains many infrared (IR) active chemical bonds. 
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Therefore, any destruction or formation of chemical bonds within PRT as a result 
of the sterilization process would likely alter the IR spectrum. The IR of freeze dried 
PRT-MP coacervate (Figure 4.4A) contained several overlapping peaks from 3500 
cm-1 to 2500 cm-1. Within this region, the amide A band (PRT backbone), a 
carboxylic acid band (C-terminus of PRT), several aliphatic bands, and N-H 
stretching bands (PRT arginine side chains) are contained. Other strong 
absorption peaks, corresponding to the amide I and amide II bands are found at 
1622 cm-1 and 1524 cm-1, respectively. The normalized spectra of control and 
sterilized samples are indistinguishable at all of these major peaks, in addition to 
other smaller peaks in the fingerprint region. Spectra of coacervates containing 
TaO (Figure 4.4B) were nearly identical to those without it, and no significant 
differences were observed between control and sterilized samples. This IR data, 
while only qualitative, demonstrates that a wide variety of IR active chemical bonds 
remained undisturbed during the e-beam sterilization process. 
 
4.4 Conclusions 
 In-situ setting PRT-MP coacervates (+/- TaO) were sterilized using 15 kGy 
of e-beam radiation.  Follow-up evaluations showed no differences in flow-
behavior, chemical composition, degradation, and gelation between sterilized and 
control groups.  This suggests that e-beam radiation will be a viable method for in 
package sterilization. While the e-beam sterilization process did not affect the 
integrity of PRT-MP coacervates, future studies must be done to validate effective 
sterilization of the material. These tests include dosimetry and microbiological 
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evaluations using test organisms. Packaging will be especially important in TaO 
containing coacervate products, as their high density will limit e-beam penetration 
considerably. If penetration problems make e-beam sterilization impractical, 
gamma radiation could be evaluated as an alternative. 
 
4.5 Materials and Methods 
4.5.1 Sample Preparation 
PRT (MP Biomedical) and MP (Sigma) were dissolved in 800 mM NaCl at 
60 mg/mL and 105 mg/mL, respectively and adjusted to pH 7.2-7.4.  When 
applicable, 35 mg/mL (30% w/w of the final coacervate) of TaO powder (Sigma) 
was added to the PRT solution.  The two solutions were mixed at a volume ratio 
of 4:1, resulting in a 1:1 charge ratio. Liquid-liquid phase separation occurred 
immediately, and the mixture was allowed to settle for 12 h at 22°C. The 
supernatant was discarded, and 5 M NaCl was added to raise the coacervate NaCl 
concentration to 1200 mM.   
 
4.5.2 E-Beam Sterilization 
 Complex coacervates were loaded using a positive displacement pipette 
into 3 mL clear polycarbonate syringes (Medallion, Merit Medical). Dry powders of 
MP, PRT, and TaO were placed in eppendorf tubes. Samples were placed inside 
a small cardboard box (75mm thick) and shipped to Sterigenics (San Diego, CA). 
The box was placed in an electron accelerator and exposed to 15 kGy of ionizing 
radiation. Nonsterilized control samples were from the same batches and tested 
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at the same time. Samples were homogenized via trituration prior to testing. 
 
4.5.3 Setting of Embolic Coacervates 
 Samples were dispensed from the syringe into a glass dish filled with 
physiological saline (1xBSS, no buffers). As solidification occurred, the sample 
was observed for integrity, foam structure, spreading, and any other differences 
between control and sterilized samples. 
 
4.5.4 Flow Behavior 
The flow behavior of PRT-MP coacervates was characterized on a 
temperature controlled rheometer (AR 2000ex, TA Instruments) using a 20 mm, 4o 
cone geometry. A solvent trap prevented the sample from drying out during the 
experiment. Shear rate was stepped from 0.01 s-1 to 500 s-1 at 10 points per 
decade. 
 
 4.5.5 31P NMR 
31P NMR was done with a Mercury 400 NMR (Varian). 50 μL coacervate 
samples were freeze dried, then redissolved in 1 mL of 6 M guanidine 
hydrochloride, containing 50 μL of D2O. If applicable, TaO was removed from the 
redissolved samples by centrifugation at 500 xg before loading 700 μL into NMR 
tubes. Dry MP samples were dissolved directly in 6 M guanidine hydrochloride. 
Chemical shifts (δ) of internal phosphates are -20 to – 25 ppm; external phosphates 
are between -5 and -9 ppm, while the degraded orthophosphates appear between 
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1-3 ppm (Figure 4.3A). 
 
4.5.6 ATR-FTIR 
ATR-FTIR was done using a Nicolet 6700 Spectrometer (Thermo 
Scientific). Coacervates were freeze dried and ground into fine powders before 
being clamped onto the diamond ATR crystal. Spectra were collected from 4000 
cm-1 to 600 cm-1, using a resolution of 4 cm-1 and an average of 512 scans. A linear 
baseline subtraction was applied before normalizing each of the spectra to its 
















Figure 4.3. 31P NMR. (A) Example NMR with peaks labeled. (B, C) Relative 









[1] B. Lambert, J. Martin, Implants, Devices, and Biomaterials: Special 
Considerations, in: B.D. Ratner (Ed.), Biomaterials Science: An Introduction to 
Materials in Medicine, Elsevier, Boston, MA, 2013. 
[2] Sterigenics, Sterilization Alternatives: Electron Beam Radiation, in: Sterigenics 
(Ed.) Oak Brook, IL, 2016. 
[3] J.A. Sugranes, Basic operating principles and validation of electron beam 
irradiation systems, J. Valid. Technol. 12(1) (2005) 42-48. 
[4] J.P. Jones, M. Sima, R.G. O'Hara, R.J. Stewart, Water‐borne endovascular 
embolics inspired by the undersea adhesive of marine sandcastle worms, Adv. 
Healthc. Mater. 5(7) (2016) 795-801. 
[5] M. Kawabe, O. Ohashi, I. Yamaguchi, Phosphorus nuclear magnetic resonance 
in polyphosphates and determination of their hydrolysis rate constants, Bull. Chem. 





SECOND GENERATION EMBOLIC COACERVATES 





Previously, endovascular embolic agents have been developed based upon 
solution dependent properties of condensed polyelectrolytes [1]. These materials 
were produced from the commercially available polyelectrolytes protamine and 
hexametaphosphate. Here, we report on the creation of a second generation 
embolic coacervate (EC). This version replaces protamine with a guanidinium-
containing synthetic copolymer, which offers tunable properties and avoids some 
of the potential adverse reactions to protamine. As before, a low-viscosity 
injectable formulation can be produced in high concentrations of NaCl. However, 
in physiological saline, the synthetic version demonstrates superior mechanical 
properties, including a 2-order of magnitude increase in dynamic shear modulus. 
The tissue response to the synthetic EC was evaluated using embolization of the 
rabbit auricular artery. Occlusion of the artery was complete and remained stable 
out to the longest timepoint, 32 days. The EC produced a neutrophilic inflammatory 
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reaction. Around 4 weeks, inflammation began to subside and fibrous tissue 
deposition was observed. Embolic coacervates represent a promising 
developmental liquid embolic agent. However, larger scale animal studies are 
needed to examine chronic tissue response and stability of occlusion. 
 
5.2 Introduction 
Embolization therapy is used for treating a wide array of conditions including 
arteriovenous malformations, aneurysms, internal hemorrhage, hypervascular 
tumors, and varicose veins [2, 3]. In a transcatheter embolization procedure, an 
embolic agent is delivered locally via a microcatheter to obstruct blood flow in a 
blood vessel or vascular bed. Liquid embolic agents are used in situations where 
distal penetration into capillaries is desired [3]. These agents have a low-viscosity 
injectable form, allowing their delivery through long microcatheters, but harden 
upon entering blood vessels. Clinical liquid embolic agents include Onyx ®, a 
solution of ethylene-vinyl alcohol copolymer dissolved in DMSO which precipitates 
in situ as the solvent diffuses away [4], and Trufill ® (NBCA), a cyanoacrylate glue 
which polymerizes upon contact with anions in blood [5]. The problems with these 
agents are well documented. The DMSO employed in precipitating systems is 
toxic, limiting injection rates, and can cause vasospasm and tissue necrosis [6, 7]. 
In addition, forward flow and distal penetration are difficult to achieve with Onyx 
[8]. Cyanoacrylate monomers polymerize rapidly and exothermically, making them 
difficult to control and causing localized hyperthermia. This rapid polymerization 
can be retarded by dispersing NBCA in ethiodized oil. However, misjudging the 
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amount for a procedure can cause the embolus to spread proximal or distal to the 
desired area [5, 9]. Moreover, if the embolic agent refluxes, the catheter can 
become permanently glued into the embolization site [10, 11]. 
The problems with liquid embolic agents have been identified, and a clincal 
need for new liquid embolic agents persists. However, the approaches to solve this 
problem, which generally fall into two distinct categories, are clinically infeasible 
for transcatheter embolization. The first approach has been to create embolic 
agents that solidify in response to temperature changes. These systems are liquids 
at room temperature and have a lower critical solution temperature near 37°C, 
which causes them to solidify in response to increasing temperature. Examples of 
this approach include poloxomers [12], N-isopropylacrylamide copolymers [13], 
and silk-elastinlike protein polymers [14]. However, because liquid embolic agents 
must be delivered by small catheters (<1 mm OD), up to 1.5 m in length, the 
embolic agents will reach 37°C before reaching the end of the catheter, causing 
them to set and obstruct the catheter prior to entering the blood vessel. A second 
approach has been to create two component systems. Separately, each 
component is soluble in aqueous solution, but phase separate into insoluble gels 
upon mixing. Examples of this type of system include mixtures of calcium and 
alginate [15], inorganic polyphosphate and divalent metal ions [16], and modified 
chitosan [17]. Because of their rapid gelation, these systems must be delivered by 
dual-lumen catheters, which can create high injection pressures due to their small 
diameters. More importantly, generating the turbulence necessary to achieve 
adequate mixing of the components at the delivery site presents an even larger 
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challenge, which could result in incomplete gelation and overpenetration of the 
embolic agent. 
Previously, we have developed water-borne embolic agents based on a 
unique setting mechanism: ionic strength triggered in situ phase inversion of liquid 
complex coacervates. This system eliminates the injection of organic solvents and 
exothermically polymerizing monomers associated with clinically available liquid 
embolic agents [1]. In the process of coacervation, solvated oppositely charged 
polyelectrolytes (PEs) condense through both ion-specific interactions and 
entropic release of counterions [18-21]. This process forms a macro liquid-liquid 
phase separation, with a polymer depleted supernatant, and a polymer-rich, fluid 
coacervate phase [22]. Here, liquid embolic coacervates (ECs) are formed in a 
high ionic strength sodium chloride solution. This salt concentration, while low 
enough to allow phase separation, dopes the coacervate with a large number of 
monovalent Na+ and Cl- ions and high water content, vastly decreasing interactions 
between oppositely charged PEs [19, 23]. When injected into solutions of 
physiological ionic strength, the concentration of freely diffusing monovalent ions 
inside the EC decreases. This, along with a decrease in equilibrium water content, 
allows for more numerous and longer-lived interactions between the oppositely 
charged PEs, resulting in solidification of the polyelectrolyte complex. 
While initial results with protamine based ECs have been promising, 
replacing protamine with a synthetic polymer reduce the risk of rare, but life-
threatening protamine specific allergic reactions [24-26]. Additionally, changing 
polymer properties, such as mol% guanidinium and molecular weight could allow 
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for tuning the properties of the coacervate in both high salt and final form. Finally, 
a synthetic polymer would eliminate environmentally-caused supply disruptions 
[27] and provide better process control. The distinguishing feature of protamine is 
its high charge density, with arginine comprising 21 of its 32 amino acids [28]. The 
guanidinium sidechain on arginine has a pKa of ~13.8 [29], making it charged 
across nearly the entire pH spectrum. Thus, synthetic polyguanidinium represents 
a logical choice for replacing protamine in ECs. Previously, guanidinium containing 
polymers have been synthesized by the McCormick and Shea groups [30-32]. 
These approaches required synthesis of a guanidinium monomer (GPMA) by 
guanidylating commercially available N-(3-aminopropyl) methacrylamide. 
Here, we built on this approach and designed a copolymer of GPMA and 
methacrylamide as a synthetic protamine analog. Following synthesis and 
characterization of the polymer, ECs were made by combining the synthetic 
polymer with hexametaphosphate, an inorganic oligophosphate. The ECs were 
formulated for injectability through microcatheters by adjusting sodium chloride 
concentration. Rheological properties of both the initial (high salt) and set forms 
(injected into saline) were characterized. Finally, we sought to examine the 
vascular response to the ECs out to 4 weeks by embolizing the central auricular 







5.3.1 Production of Synthetic Guanidinium Polymer 
First, 3-guanidinopropyl methacrylamide (GPMA), was synthesized by 
guanylation of 3-aminopropyl methacrylamide (APMA) using 1H-pyrazole-1-
carboxamidine hydrochloride (Figure 5.1) [33]. After purification, the product was 
analyzed using NMR and mass spectroscopy. In 1H NMR, the conversion of APMA 
to GPMA most notably caused a downfield shift of the (-CH2-amine/guan) peak 
from 2.88 to 3.10 ppm, along with a slight deshielding of the vinyl peaks (~0.03 
ppm). No residual APMA peak remained at 2.88 ppm (Figure 5.2). In 13C NMR, the 
guanidinium carbon in GPMA became apparent at 156.6 ppm, and a slight 
deshielding of the (-CH2-amine/guan) peak was also observed, from 37.0 to 38.7 
ppm (Figure 5.3). Finally, ESI mass spectrometry (Figure 5.4) showed formation 
of the GPMA product at 185.40 Da, nearly identical to the predicted value of 185.2 
Da. Importantly, there was no remaining APMA (143.2 Da), or emergence of the 
diguanidine monomer side product (228.2 Da). However, HPLC analysis on a C18 
column did show a small amount of the APMA starting material. Together, these 
results confirmed the production of GPMA monomer, which was used to make the 
synthetic protamine analog. 
 
5.3.2 Production of p(GPMA-co-MA) 
Reversible addition fragmentation chain-transfer (RAFT) polymerization 
was used to prepare copolymers of GPMA and methacrylamide (MA) with a 
controlled molecular weight and low polydispersity index (PDI) (Figure 5.5). A 
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molecular weight of 20 kDa was targeted, and a monomer feed ratio of 80% GPMA 
and 20% MA was selected. The reaction was done in an aqueous acetate buffer, 
pH 5.3. To set polymerization parameters, the kinetics of this reaction were studied 
(Figure 5.6). The rate of polymerization was directly proportional to monomer 
concentration out to 16 h, as indicated by the pseudo-first order plot in Figure 5.6 
B. In addition, this reaction had a minimal induction period and reached 90% 
monomer conversion (Figure 5.6 C). Correspondingly, refractive index traces from 
GPC (Figure 5.6 A) show a decrease in elution volume and increase in peak 
intensity, consistent with a growing polymer out to 16 h From 16 to 20 h, no 
increase in conversion or elution volume was seen; thus, the polymerization time 
was set at 16 h for future reactions. Additionally, the slight shielding of the vinyl 
peaks in GPMA relative to MA (0.1 ppm) allowed us to compare reactivity of the 
two monomers: the ratio of unreacted GPMA:MA stayed constant throughout the 
20 h time course, indicating equal reactivity. 
Next, large scale polymer synthesis (batch size 6-20 g) was performed eight 
times, which typically yielded around 50% after conversion to the hydrochloride 
salt and ultrafiltration. SEC analysis with light scattering was used to determine 
molecular weights and size distributions with an experimentally determined dn/dc 
value of 0.1782. A representative SEC profile (RI) from a purified polymer is shown 
in Figure 5.7. In large scale polymerizations, average molecular weight (Mn) was 
18.6 kg/mol (+/- 2.3 kg/mol), and PDI was 1.08 (+/- 0.05). GPMA content was 78 
mol% (+/- 2.6%), as determined via 1H NMR. 
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5.3.3 Formation of Embolic Coacervates 
 ECs were formed using the synthetic p(GPMA-co-MA) (PG) and sodium 
hexametaphosphate (MP). For comparison of synthetic PG to the naturally 
occurring polyelectrolyte protamine (PRT), coacervates were also made with PRT 
and MP. Commercial MP is a mixture of inorganic phosphate oligomers, both cyclic 
and linear, usually containing 10-20 phosphorous atoms per chain [34-37]. In their 
fully ionized form, cyclic inorganic polyphosphates have the formula (PnO3n)n-, 
while the linear form is comprised of (PnO3n+1)n+2-. Regardless of the whether the 
polyphosphate is linear or cyclic, each phosphorus atom has one strongly ionized 
hydrogen, with a pKa of ~4.5 or less [34, 38]. The weakly acidic end groups of 
linear polyphosphates are usually dissociated between pH 4.5 and 9.5 [34, 39]. 
Overall, this contribution to charge density is relatively small, so 1 charge per 
phosphorous atom was assumed at pH 7.2. The strongly basic GPMA sidechains 
on the polymer were considered fully protonated. Polyelectrolyte complexes of PG 
and MP were made in a series of salt concentrations (Table 5.1). From 150 mM to 
800 mM NaCl, cloudy gels were formed with yields of 12%-8% of total batch 
volume, respectively. Between 800 mM and 1200 mM NaCl, the cloudy complexes 
became fluid, clear coacervates, and yield dropped precipitously to only 2.5% of 
total batch volume. Therefore, to generate clear, flowing ECs while maintaining 
high yield, coacervates were first formed in 800 mM NaCl. After removal of the 
supernatant, salt content of the coacervate was raised by mixing 5 M NaCl into the 
condensed phase. Unless otherwise noted, 30 wt.% tantalum metal powder was 
added to the complex as a radiocontrast agent, necessary for the delivery of the 
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embolic agent under fluoroscopic guidance. 
  
5.3.4 Formulation of Injectable EC and Flow Behavior 
For delivery, liquid embolic agents must have a viscosity that allows for 
injection through microcatheters without exceeding their rated burst pressure. 
Clinically used embolic microcatheters have rated pressures of 5-8 MPa; thus, an 
injection pressure less than 4 MPa at 0.3 mL·min-1, the maximum injection rate of 
current liquid embolics, was set as a design specification. To formulate an EC that 
met this limit, viscosity of the EC was lowered by increasing the amount of NaCl in 
the coacervate. Corresponding changes in injection pressures were determined in 
model catheters. The model catheters have the same inner surface (PTFE) and 
internal diameter (0.026”) as commonly used 3 F embolic catheters. ECs were 
loaded into 1 mL syringes and a syringe pump, equipped with a force transducer, 
was used to measure the steady state injection force through the model catheter 
at 0.3 mL min-1 (Figure 5.8). Using the bore diameter of the syringe, the measured 
forces were converted to pressure and extrapolated to a catheter length of 135 cm, 
the most common length used in the clinic. At 1200 mM, injection pressure was 
10.1 MPa, exceeding the limits of clinically used catheters. Increasing NaCl 
concentration drastically reduced injection pressures, with 1400 mM NaCl being 
sufficient to lower injection pressures below 4 MPa (3.25 MPa). A further increase 
in NaCl concentration resulted in lower injection pressure. However, to minimize 
the amount of salt injected, an NaCl concentration of 1400 mM was chosen for 
further development. 
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After fixing the NaCl concentration at 1400 mM, the viscosity of both PG-
MP and PRT-MP ECs was investigated over a range of shear rates (0.1-500 s-1) 
to simulate transcatheter delivery (Figure 5.9). PG-MP without Ta demonstrated 
slight shear thinning within the first decade of shear rates, but was nearly 
Newtonian, from 1 to 500 s-1, with a viscosity of 1.1 Pa·s. Adding Ta more than 
doubled the viscosity at low shear rates (~5 Pa·s). However, by 10 s-1, the material 
shear thins to a viscosity approaching PG-MP (-Ta) (1.2 Pa·s). The flow behavior 
of polymer-based ECs in this high NaCl concentration was nearly indistinguishable 
from PRT-MP with Ta. Using these viscosity measurements and Poiseuille's Law, 
injection pressures can be predicted. Here, the predicted injection pressures for 
PG-MP are roughly 60% of the experimentally determined values (2 MPa). 
 
5.3.5 Viscoelasticity of PG-MP ECs 
Next, the viscoelastic properties of ECs were compared before and after 
solidification in balanced salt solution (BSS). This was done using rheological 
frequency sweeps, where a fixed oscillatory strain (1%) was applied at a series of 
stepped frequencies (0.1 to 10 Hz). These frequency sweeps are shown in Figure 
5.10, and dynamic rheological properties at 1 Hz. are compared with statistical 
analysis in Figure 5.11. In high salt, the fluid PG-MP EC is a viscously dominated 
fluid with a complex modulus (G*) of 0.025 kPa at 1 Hz. Upon solidification in BSS, 
G* increased by almost 4 orders of magnitude at the same frequency (195 kPa). 
Additionally, the ECs transitioned from a liquid to a viscoelastic material, which 
demonstrated a crossover to solid-dominated (elastic) behavior (G’>G”) at 5.2 Hz.  
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Without Ta, the material was less elastic, with crossover frequency at 17 Hz. 
Furthermore, the presence of Ta had a statistically significant effect (p<0.05) on 
the complex modulus, increasing G* by approximately 75%. Similarly, PRT-MP 
ECs also set in BSS, but G* only increases ~2 orders of magnitude.  In contrast to 
PG-MP, the final form of PRT-MP remained viscously dominated, with G” 
significantly higher than G’ over the entire frequency range. Furthermore, PG-MP 
had complex moduli (G*) 2 orders of magnitude higher than that of PRT-MP. 
 
5.3.6 Evaluation of Catheter Entrapment 
 With both cyanoacrylate glues and precipitating liquid embolics, the 
catheter can become glued into the injection site by the embolic agent [10, 40]. 
Thus, gauging the risk of catheter entrapment is important for developmental liquid 
embolic agents. Here, the force required to remove the catheter from solidified ECs 
was measured both 2 min and 24 h after injection of the EC into saline. Sections 
of 3 F catheters were embedded into 1 cm of EC. After allowing the EC to solidify 
in saline, the force required to remove the catheter from the embolic plug was 
measured at 2 min and 24 h. At 2 min, the force required to remove the catheter 
at 1 cm·s-1 was 16.7 mN (+/- 5.8 mN). Even in the worst-case scenario (24 h), the 
force required to remove the embolic was only 384 mN (+/- 107 mN). Additionally, 
no embolic agent remained adhered to the catheter upon removal. These results 
suggest that adhesion to the catheter is not a problem with embolic coacervates 
and that catheter entrapment does not present a major risk with this system. 
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5.3.7 Rabbit Auricular Artery Embolization 
 To examine the perivascular tissue response to the synthetic ECs, auricular 
artery embolization was performed in rabbit ears. This model is advantageous 
because it allows for simple access to the target blood vessel and easy 
visualization of the embolic agent. It has been used previously as a fast-flow vessel 
model to study a range of prospective embolic agents, including particle and liquid 
embolics [12, 16, 41-44]. Additionally, the rabbit ear contains multiple 
arteriovenous anastomoses, which allow collateral blood flow and help to localize 
any ischemic effects resulting from embolization [45, 46]. Eight rabbit ear 
embolizations were performed, and animals were sacrificed at timepoints ranging 
from 1-32 days. Before the procedure, a topical anesthetic cream was applied to 
the ear. Embolization was performed by gaining retrograde access to the central 
auricular artery with an intravascular catheter. The catheter was flushed with saline 
to confirm positioning, before continuously injecting approximately 25 μL of EC to 
fill ~2 cm of the artery. With backlighting of the ear, ECs were observed to 
completely fill the targeted section of the central auricular artery (CAA). In one 
case, the central auricular vein (CAV) was injected. Setting of the ECs occurred 
within seconds, after which, the embolus did not migrate. No hematomas or 
bleeding from the access site was observed, indicating achievement of 
hemostasis. 
After embolization, the gross tissue response at the embolization site was 
monitored daily. No signs of discomfort or irritation were seen in any of the animals. 
The embolic plugs demonstrated positional stability, and no migration or 
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fragmentation was observed over the 4 week course of the experiment. The 
progression of the gross response is shown for the longest timepoint (Figure 5.12). 
Gross inflammation appeared to reach a peak 4-7 days after embolization, as 
visualized by redness surrounding the embolization site. Over the next week, this 
response appeared to subside. At this point, the embolus remained clearly visible 
and moderately swollen. After 2 weeks, the macroscopic appearance changed little 
throughout the rest of the study. Ears remained healthy, and no visible signs of 
tissue necrosis were seen in any of the animals. 
 
5.3.8 Histological Evaluation 
 Postmortem, the embolized ears were removed, fixed in 10% formalin, and 
cut into sections. Sections containing the embolus and adjacent proximal and distal 
sections were embedded in paraffin and stained for histological evaluation. The 
ECs were observed to completely occlude the CAA, and no sign of 
revascularization was present out to 32 days. There was also evidence of reduced 
blood flow distal to the EC, as the arteries appeared collapsed and contained 
native thrombus. Proximally, vessels became more patent farther away from the 
embolus. In arterially embolized ears, no embolic agent was seen in venous 
circulation. Within the embolized arteries, a progressive inflammatory response, 
dominated by neutrophils, was seen. The progression of this response is shown 
with histological sections of the embolized CAA in Figure 5.13. One day after 
embolization, there was little damage to the vessel wall, but perivascular 
inflammation was present. This early-stage inflammation was indicated by the 
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presence of neutrophils surrounding the embolized vessel. Neutrophils are highly-
mobile phagocytic granulocytes which arrive at the site of inflammation by 
migrating through the bloodstream and extravasate into the tissue through 
chemotaxis. This process is evident in Figure 5.13 B (high magnification; 1 day), 
as neutrophils can be seen extravasating from the longitudinally sliced blood 
vessel on the left and migrating toward the EC-filled CAA. By day 4 (Figure 5.13 
C), the structure of the vessel wall is compromised, likely through enzymes 
secreted by neutrophils which degrade collagen and elastin. From days 4-14, 
progressive vessel wall obliteration continued, perivascular neutrophilic 
inflammation became more severe, and the nodule of inflammation grew. At 14 
days (Figure 5.13 E), significant neutrophil ingrowth can be seen within the EC, as 
the inflammatory response begins to degrade the material. By the longest 
timepoint at 32 days (Figure 5.14), most of the tantalum was removed from the 
embolus due to phagocytosis. At this point, neutrophils remained the predominate 
cell type within the lesion, but globules of EC and Ta left behind were being actively 
phagocytosed by macrophages (Figure 5.14 B). The vessel structure was also 
destroyed; however, inflammation had greatly diminished. Additionally, there was 
deposition of fibrous connective tissue surrounding the nodule of inflammation 
(Figure 5.14 C).  
In one ear, the central auricular vein, which lies close to the CAA was 
unintentionally accessed and injected with EC. Grossly, the ear appeared normal 
with little inflammation observed, and the animal was kept until 29 days. Upon 
histological sectioning, no material was found within the CAA. However, the vein 
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was occluded with the EC (Figure 5.15). In this specimen, neutrophilic 
inflammation appeared milder than in the arterially embolized ears. This 
inflammatory response had destroyed the vessel endothelium and tunica media. 
However, in this case, the inflammatory response was confined inside the layered 
collagen of the tunica adventitia, which remained intact. As seen in the artery, 
phagocytosis had removed a majority of the Ta powder from the embolization site, 
and collagen deposition by fibroblasts was seen (Figure 5.15 C).  
 
5.4 Discussion 
First-generation embolic coacervates were composed of protamine and an 
oligophosphate [1]. Here, a methacrylamide-based synthetic guanidinium 
copolymer is reported as a substitute for protamine in producing ECs. The 
synthetic polymer can be produced via RAFT polymerization, which allows for a 
well-controlled molecular weight and polydispersity, preventing production 
problems resulting from endogenous heterogeneity and supply disruptions with the 
natural product [27]. Furthermore, the randomly-ordered, nonimmunogenic nature 
of synthetic polymers makes them far less likely to incite severe IgG-mediated 
immune responses, a risk associated with endovascular administration of PRT. 
As seen with PRT, polyelectrolyte complexes (PECs) of this synthetic 
polymer and hexametaphosphate have morphologies and rheological properties 
strongly dependent on salt concentration. To formulate a low-viscosity embolic 
coacervate deliverable via embolic microcatheters, the NaCl concentration of the 
coacervate was increased to 1400 mM. At this high salt concentration, the 
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interactions between the oppositely charged PEs, which exist in a state of dynamic 
equilibrium, are relatively few and short-lived, resulting in a low-viscosity fluid 
coacervate. This behavior is driven by the presence of high concentrations of 
monovalent ions and water in the coacervate, which plasticize interactions 
between the PEs [23, 47]. In this high salt concentration, the pressure required to 
inject the synthetic EC at 0.3 mL·min-1 through a 3 F model catheter (135 cm) was 
3.25 MPa, which is well below the burst pressure of most embolic microcatheters 
(5-8 MPa). This injection pressure was approximately 60% higher than those 
predicted by rheological flow curves, a more drastic difference than was seen 
previously with protamine and phytic acid [1]. While some of this increased 
pressure results from non-Newtonian behavior at low shear rates, most of it is likely 
due to interactions between the material and catheter wall. Injection pressure has 
an r4 inverse proportionality (r=radius of the catheter), meaning that any adhesion 
of the material to the catheter wall and subsequent lowering of the effective 
diameter drastically affects injection pressure. 
When the EC is injected into a lower-ionic strength environment, such as a 
blood vessel (~150 mM), Na+ and Cl- ions are free to diffuse in and out of the 
complex. As the salt concentration within the polyelectrolyte complex decreases, 
water becomes excluded, and polyion pairing becomes less shielded by 
monovalent ions. This allows higher numbers of interactions between the 
oppositely charged PEs and increases their kinetic stability, producing a phase 
transition of the complex from a liquid coacervate to a viscoelastic material. This 
transition can be seen in the rheological data for synthetic ECs (Figures 5.10, 
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5.11). In 1400 mM NaCl, PG-MP was a weak, purely viscous liquid with loss 
modulus (G”) considerably higher than the storage modulus (G’) over the entire 
range of frequencies. After injection into physiological saline, the PG-MP complex 
became a strong viscoelastic material, with complex modulus (G*) increasing 
nearly 4 orders of magnitude (0.025 to 195 kPa). In physiological saline, 
differences in mechanical properties between ECs made with PRT and with PG 
are dramatic. While PRT-MP does harden significantly, PRT-based ECs remain 
viscous fluids after injection into BSS, which contrasts with the viscoelasticity seen 
with PG-MP.  Furthermore, the complex moduli of PG-MP are more than two 
orders of magnitude higher than PRT-MP. This drastic difference in mechanical 
properties was only evident in low salt concentrations, as the two systems behave 
almost identically in 1400 mM NaCl (Figure 5.9). Molecular weight (18 kDa vs. 5 
kDa) likely accounts for part of this difference, as increased molecular weight has 
been shown to favor a solid morphology [48]. The fraction of guanidinium 
sidechains (78 mol% vs. 65 mol%) was also increased in the synthetic polymer, 
but the charge density per unit mass remained the same (4.1 mol/g). Furthermore, 
lowering the water content within a PEC strengthens mechanical properties 
through decreased polymer mobility and increased PE interactions [19, 47]. 
Because the aliphatic backbone of the synthetic polymer is more hydrophobic than 
the peptide backbone in PRT, additional water may be excluded from PG-MP 
complex in low salt resulting in stronger mechanical properties in the PEC [49]. 
The contribution and magnitude of each of these effects on mechanical properties 
of the complexes are an avenue of future study with the synthetic polymers. 
109 
The ability of synthetic polymer-based ECs to transition from low-viscosity 
injectable liquids, to strong viscoelastic materials gives them clinical utility as 
embolic agents. For comparison, rheological characterizations of clinically 
available embolic agents, such as Onyx ®, are difficult to find in the literature. 
However, the elastic and complex moduli of PG-MP (>100 kPa) are more than 2 
orders of magnitude higher than PRT ECs as well as several other systems that 
have demonstrated efficacy in animal models [50-52]. These values also compare 
favorably to reported values for native whole blood and fibrin clots (2-600 Pa) [53-
55], allowing them to structurally support stable occlusion of blood vessels. Despite 
their strong rheological properties, a minimal amount of force (<0.4 N or 1.4 oz) 
was required to remove catheters solidified ECs, demonstrating that catheter 
entrapment is unlikely to present a clinically significant problem with this 
embolization agent. 
After embolization of rabbit ears, ECs incited a neutrophilic inflammatory 
response. Neutrophils are phagocytes responsible for removal of foreign materials 
and damaged tissue, which are typically the predominate cell type in an 
inflammatory nidus within the first few days. Presence of neutrophils beyond this 
point can indicate chronic non-healing [56]. Here, neutrophils decreased 
significantly from 2 weeks to 4 weeks and were replaced by increasing numbers 
of macrophages and some fibroblasts. This decrease in inflammation and 
associated presence of fibroblasts indicates the beginning of a proliferative phase 
of healing [56]. Continuation of the processes seen here would likely result in full 
resorption of the material and formation of fibrous scar tissue in place of the blood 
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vessel. The eventual fate of this fibrotic tissue is unclear. Even with ‘permanent’ 
embolic agents, high rates of revascularization are seen [57-61]. Accordingly, 
Onyx® and Trufill ®, the two liquid embolics in widespread clinical use, are only 
approved by the FDA for embolization of AVMs destined for later surgical 
resection. Considering the obliteration of vessel structure, it seems unlikely that 
revascularization will proceed by recanalization of the previous vessel lumen. 
Arterial blood flow to the surrounding tissue would probably be restored via a 
combination of enhancement of extant collateral blood flow and 
neovascularization. While no revascularization was seen in this preliminary 1 
month study, examining the spatial and temporal stability of the occlusion is an 
important objective of future larger scale in vivo experiments. 
Another important histological finding from this study was that the small 
tantalum particles were easily phagocytosed and removed from the embolization 
site by neutrophils and macrophages. The Ta used in this study (1-5 μm) are within 
the optimal range for macrophage phagocytosis [62, 63]. The phagocytosed Ta 
would likely be transported to the regional lymph nodes. Avoidance of 
phagocytosis is dependent upon particle shape, but generally particles larger than 
the macrophage cell volume are not readily phagocytosed [64]. Larger Ta particles 
would likely avoid phagocytotic clearance, but might incite a more persistent 
inflammatory response and formation of significant numbers of foreign body giant 
cells.  
A complication in examining tissue responses to embolic agents is 
separating material specific effects from natural biological responses to ischemia. 
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Neutrophils are largely responsible for clearing out cellular debris from a wound 
site [56]. Especially within the arterial system, occlusion causes tissue 
degeneration and necrosis due to ischemia, creating an overwhelming amount of 
cellular debris. This loss of nutrition also compromises arterial wall integrity 
resulting in upregulation of various proinflammatory transcription factors and 
cytokines [65]. These factors could be responsible for the extended presence of 
neutrophils seen here. At 4 weeks after venous embolization with the EC, the 
collagen layer surrounding the vessel, tunica adventitia, was still intact. Neutrophils 
secrete a variety of enzymes that degrade collagen and elastin, and thus, this 
intact layer suggests that neutrophilic inflammation was less severe in the days 
after embolization than in the arterial embolizations. Localized ischemia is much 
less severe with venous occlusion and could be the reason for the reduced 
neutrophil-mediated response and increased proliferation in this specimen. 
While its severity varies with choice of embolic agent and site of 
embolization (or animal model), all embolic agents incite inflammation. Onyx ® has 
been shown to incite perivascular inflammation and cause angionecrosis in both 
animal models and resected human AVMs [57, 66]. Cyanoacrylate glues incite 
heavy neutrophilic inflammation and total destruction of vessel wall architecture 
[61]. Intraluminal and mural infiltration of neutrophils and monocytes, focal 
angionecrosis, and formation of foreign body giant cells are seen after 
embolization with polyvinyl alcohol particles [58, 60, 67]. Here, the severe 
inflammation seen here at early timepoints did subside by day 28, but the vessel 
wall was largely destroyed even in the venous injection. The eventual resolution of 
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this inflammatory response and its impact on surrounding tissues warrants further 
investigation. Utilizing more sophisticated animal models with interventional 
radiology techniques, such as embolization of the swine rete mirabile will provide 
a more complete picture of the tissue response and better comparison with current 
embolization agents. In addition, subcutaneous injection of the EC could be used 
to examine the tissue response in the absence of ischemia. 
 
5.5 Conclusion 
First generation embolic coacervates were comprised of protamine, a 
natural polycation with 65 mol% positively charged guanidinyl sidechains, and an 
oligophosphate. To provide better design control and preclude hypersensitivities 
associated with endovascular administration of protamine, a synthetic polycation 
was produced which mimics the high charge density and guanidinium content of 
protamine. Coacervates of this polymer, poly(3-guanidinopropylmethacrylamide-
co-methacrylamide), and hexametaphosphate display a greater change in 
properties with decreasing ionic strength: they have a similar viscosity in their 
injectable form and possess vastly stronger mechanical properties in their set form. 
Embolization of 8 rabbit auricular arteries was performed, and at the longest 
timepoint (1 month), occlusions remained stable. No signs of direct cytotoxicity 
were observed. Histological evaluation showed inflammation comparable to 
current embolization agents. While embolic coacervates represent a promising 
new liquid embolic, a thorough investigation of the long-term fate of the embolus 
and surrounding tissue is still needed. 
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5.6 Materials and Methods 
5.6.1 Reagents 
N-(3-aminopropyl) methacrylamide hydrochloride (APMA) was obtained 
from Polysciences, Inc. (cat# 21200). 1H-Pyrazole-1-Carboxamidine 
hydrochloride was purchased from Chem-Ipex International (cat# 21678). 
Methacrylamide (MA; L15013) and glacial acetic acid (cat# 36289) were obtained 
from Alfa Aesar. 4-methoxyphenol was purchased from TCI chemicals (cat 
#M0123). 4,4′-Azobis(4-cyanovaleric acid) (V501; cat# 11590) and 
azobisisobutyronitrile (AIBN; cat# 441090) were obtained from Sigma-Aldrich. 4-
Cyano-4-(thiobenzoylthio)pentanoic acid was purchased from Strem Chemicals 
(cat# 16-0422). Sodium acetate was obtained from VWR (cat# 0602). USP grade 
sodium chloride (NaCl; cat# 102892) and protamine sulfate (PRT; cat #102752) 
were purchased from MP Biosciences. Triethylamine (TEA) was obtained from 
Fischer Scientific (cat# # BP616-500). Tantalum metal powder (1-5 micron particle 
size) was purchased from Atlantic Equipment Engineers, Inc. (cat# TA-101). All 
solvents were ACS grade or better. Solutions were made in ultrapure double 
deionized water. 
 
5.6.2 Synthesis of GPMA Monomer 
N-(3-methacrylamidopropyl) guanidinium chloride (GPMA) was synthesized 
(Figure 5.1) using procedures adapted from the literature [32, 33]. Briefly, a flask 
was charged with N-(3-aminopropyl) methacrylamide hydrochloride (APMA) (20 g; 
112 mmol) and the inhibitor 4-methoxyphenol (0.2 g; 1.6 mmol). DMF (112 mL) 
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was added to dissolve APMA at a concentration of 1 M. TEA (18.7 mL; 134 mmol) 
was added to the flask and the mixture was stirred for 5 min under N2. Next, 1H-
pyrazole-1-carboxamidine hydrochloride (16.4 g; 112 mmol) was added. The 
mixture was reacted at 20°C under N2. After 16 h, TEA·HCl salts were separated 
from the reaction mixture by vacuum filtration using a Büchner funnel. The 
monomer was extracted with diethyl ether 3 times, forming a dense oil. Finally, the 
monomer was collected dried under vacuum. The product was confirmed by proton 
and carbon NMR. 1H NMR (400 MHz, D2O): δ (ppm) 1.68 (q, CH2-CH2- CH2), 1.77 
(s, CH3), 3.08 (m, CH2-N), 3.18 (m, CH2-N), 5.30 (s, =CH2), 5.55 (s, =CH2).  13C 
NMR: (400 MHz, D2O) δ (ppm) 17.74 (CH3), 27.62 (CH2), 36.62 (CH2-N), 38.71 
(CH2-N), 121.13 (C=CH2), 138.83 (CH2=C), 156.6 2(C), 171.55 (C=O). Formation 
of GPMA was also verified by ESI mass spectroscopy (185.1 Da). 
 
5.6.3 RAFT Polymerization of GPMA and MA 
Synthesis of p(GPMA-co-MA) was adapted from that of similar polymers by 
Treat et. al. [30]. RAFT polymerization was employed using 4-cyano-4-
(thiobenzoylthio)pentanoic acid as the chain transfer agent (CTA) and V-501 as 
the initiator at a 5:1 molar ratio. A fixed molar ratio of 80:20 (GPMA:MA) and 
molecular weight of 20 kD were utilized. GPMA (9.12 g, 41 mmol), MA (0.88 g, 10 
mmol), 4-cyano-4-(thiobenzoylthio)pentanoic acid (112 mg, 0.400 mmol), and V-
501 (22.4 mg; 0.080 mmol) were dissolved in 1 M (pH 5.3) acetate buffer (52 mL). 
The resulting solution was degassed by bubbling for 2 h with N2 before being 
septum sealed. The reaction was kept under N2 while it proceeded at 70°C for 16 
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h (Figure 5.2 A). The resulting polymer was cooled, exposed to air, and 
precipitated in acetone. For end group modification, the polymer was redissolved 
in methanol (~ 100 mL), and AIBN (1.3 g, 8 mmol) was added (Figure 5.2 B). The 
solution was degassed and reacted under N2 for 4 h at 60°C. The product was 
precipitated in acetone, collected by filtration, and dried under vacuum. A Millipore 
ultrafiltration system equipped with a Pellicon 2 Minicassette (Biomax ® 5 kDa) 
was used to purify the final product. To convert the polymer to the hydrochloride 
salt, PG was dissolved in DI water and washed with a 20x volume of 150 mM NaCl 
at pH 3 (adjusted with HCl). Next, an additional 20x volume exchange was 
performed with DI water. Finally, the purified retentate was freeze dried. 
For polymerization kinetics, aliquots the reaction mixture (1 mL each) were 
dispensed into glass ampules. The aliquots were bubbled with nitrogen for 1 h, 
sealed, and placed in a 70°C oil bath. At each designated timepoint (0, 1, 2, 4, 5, 
6, 10, 12, 16, and 20 h), samples were quenched by bubbling with air and freezing 
at -20°C. GPC was run directly on the quenched reaction mixture (as described 
below). For 1H NMR, the quenched reaction mixtures were lyophilized and 
reconstituted in D2O using 2 mg/mL DMSO as an external standard. The 
integration values of the vinyl peaks were compared to that of the constant DMSO 
external standard to follow remaining monomer concentration and conversion. 
 
5.6.4 Polymer Characterization 
The polymer was characterized by aqueous size exclusion chromatography 
(SEC) on an Aglient HPLC 1260 Infinity equipped with refractive index detector 
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and a Wyatt miniDAWN TREOS light scattering detector. An elutent of 1 wt% 
acetic acid in 0.1 M LiBr (pH=3.3) was run at 1 mL/min on an Eprogen CATSEC 
300 column. Kinetics runs were analyzed on a CATSEC 100 column. For 
molecular weight analysis using light scattering, the dn/dc value for p(GPMA-co-
MA) was determined (0.1782) by injecting known stock solutions of PG ranging 
from 0.25-2 mg/mL at 1 mL/min using a syringe pump (PHD Ultra, Harvard 
Apparatus). Final monomer composition was calculated using 1H NMR. 
 
5.6.5 Production of Embolic Coacervates 
Coacervates of PG and MP were prepared with 1-5 μm Ta powder added 
as a radiocontrast agent (30 wt% of final coacervate), unless otherwise noted. 
Aqueous stock solutions of PG and MP were made at 100 mg/mL and 200 mg/mL, 
respectively. The pH of both solutions was adjusted to 7.2. Coacervation was 
achieved by sequential addition of DI water, 5M NaCl, MP solution, Ta powder, 
and PG solution, while mixing with an overhead mixer. In this final mixture, PG 
concentration was fixed at 50 mg/mL; MP concentration was 42 mg/mL based 
upon calculated charge densities and a 1:2 charge ratio. Amounts of DI water and 
5 M salt were adjusted to form an NaCl concentration of 800 mM. Phase separation 
occurred immediately upon addition of PG, and the coacervate was allowed to 
settle for 12 h. Afterwards, the supernatant was removed and 5 M NaCl was mixed 
into the condensed phase using trituration to bring the overall [NaCl] in the 
coacervate to its final concentration (1400 mM, unless otherwise noted). PRT-MP 
coacervates were prepared using the same method, substituting PRT for PG. 
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5.6.6 Injection Pressures 
For pressure measurements, 22 gauge dispensing tips (Jensen Global Inc.)  
were glued into 50 cm lengths of 23 gauge PTFE tubing (Zeus Inc.), which have 
an internal diameter (0.026 in.) closely matching that of clinically used 3 F 
catheters. ECs in 1 mL syringes (Medallion, Merit Medical Inc.) were warmed to 
37°C, and attached to the tubing. The tubing was placed in a 37°C water bath and 
the coacervate was injected at the 0.3 mL·min-1 using a syringe pump (PHD Ultra, 
Harvard Apparatus). To measure injection forces, a compression load cell (iLoad 
Mini, Loadstar Sensors) was attached to the syringe pump between the driver and 
the syringe plunger. Steady state injection forces were measured and converted 
to pressure using the bore diameter of the syringe (4.8 mm). Injection pressures 
were measured in 50 cm model catheters, but converted to those that would be 
generated in 135 cm catheters using a linear conversion, as predicted by 






where P is pressure, r is the radius of the tube, L is the length of the tube, Q is the 
volumetric flow rate, and µ is viscosity. This linear conversion was also verified 
experimentally in our model. Poiseuille's law was also used to compare measured 





The complex fluid behavior of ECs was characterized on a temperature 
controlled rheometer (AR 2000ex, TA Instruments) at 37°C. High salt (1400 mM) 
samples were analyzed using a 4° cone and plate geometry equipped with a 
solvent trap to prevent evaporation during the experiment. First, an oscillatory 
frequency sweep from 0.1 to 10 Hz with a fixed strain of 1% was used to examine 
viscoelastic properties. Next, viscosity was evaluated as shear rate was stepped 
from 0.1 s-1 to 500 s-1 at 10 points per decade. A 20 mm flat plate geometry was 
used for rheological evaluation of the ECs in physiological saline. Adhesive 
sandpaper was cut to size with a laser cutter and attached to the geometry to 
prevent slippage (1 mm gap). The ECs were injected into BSS atop the geometry 
in a circular mold and allowed to equilibrate for 12 h before loading onto the 
rheometer. An oscillatory frequency sweep was done using the same method as 
the high salt ECs.  
 
5.6.8 Catheter Pull-Out Force 
 ECs were injected into filtration tubes (Supelco, Inc.; cat #57240-U) to a 
height of 1 cm (~300 μL of EC).  A cut section (~10 cm in length) of 3 F catheter 
(Renegade HI-FLO, Boston Scientific Inc.) were placed in the center of each EC-
filled tube. The filtration tubes were completely submerged in a dish containing 
BSS and allowed to incubate. At predetermined intervals of 2 min and 24 h, the 
force required to remove the catheter from the solidified EC was measured on an 
Instron 3342 materials tester (Instron, Inc.) equipped with a 10 N load cell and 
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controlled with Bluehill 3 software. The catheter was removed in extension mode 
with a strain rate of 600 mm·min-1.  
 
5.6.9 Rabbit Auricular Artery Embolization 
The subchronic tissue response to ECs was evaluated in a rabbit auricular 
artery model. All animal studies were carried out in accordance with the University 
of Utah IACUC guidelines and approved protocols. One hour prior to the 
procedure, the rabbit was weighed, the ear was shaved and cleaned with 70% 
isopropyl alcohol, and a local anesthetic cream (EMLA) was applied topically. 
Buprenorphine (Buprenex) was also given to prevent pain or irritation. Immediately 
before the procedure, EMLA was reapplied to the ear to dilate the blood vessels. 
A sterile 24 gauge intravascular catheter (BD Medical) was advanced into the 
central artery of the ear within the distal third. The central needle was withdrawn 
from the catheter, and before embolizing, the catheter was flushed with saline to 
confirm arterial positioning. The embolic agent was injected to fill ~2 cm of the 
artery (~ 25 μL) as the catheter was slowly retracted. After 2 min, the catheter was 
completely removed, and pressure on the artery was maintained. Embolization 
was verified visually. The embolic plug was monitored for signs of movement for 
10 min. At the designated timepoints, the animals were euthanized by first sedating 
the animals with ketamine/xylazine (IM) followed by intravenous injection of 
euthanasia solution (VetOne). During necropsy, ear tissue was harvested and 
fixed with 10% buffered formalin. After 1 week, the ears were cut into small 
sections (~4 cm2). Tissue sections within the embolization site were collected, in 
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addition to proximal and distal sections. Sections were embedded in paraffin and 
sectioned prior to staining with hematoxylin and eosin and Masson’s trichrome. 
 
5.6.10 Statistical Analysis 
 Unless otherwise noted, values reported here represent an average of three 
runs +/- standard deviation. Using IBM SPSS Statistics 24 software, one-way 







Figure 5.1. GPMA monomer synthesis. 3-Guanidinopropyl methacrylamide 
(GPMA) was produced by guanylation of 3-Aminopropyl methacrylamide (APMA). 
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Figure 5.2. 1H NMR of APMA and GPMA. Production of GPMA product is 




Figure 5.3. 13C NMR of APMA and GPMA. Formation of the GPMA product is 





Figure 5.4. ESI mass spectrum of GPMA. The GPMA product is found at 185.1 




Figure 5.5. Production of p(GPMA-co-MA). (A) Aqueous RAFT polymerization of 
GPMA and MA followed by (B) End-group modification to remove CTA. Structures 





Figure 5.6. RAFT polymerization kinetics. (A) RI traces from GPC. (B) Pseudo-first 








Table 5.1. Properties of PG-MP PE complexes at various NaCl concentrations. 
Volume yield is a percent of overall batch size (i.e. with a 10% yield, a 1 mL batch 
produced 100 μL of coacervate). A dramatic drop in yield from 800 mM to 1200 







Figure 5.8. Injection pressures. (A) Illustrative raw force profile for single run.  (B) 
SS injection pressures for PG-MP (+Ta) in 135 cm catheters, 0.026” ID vs. [NaCl]. 




Figure 5.9. Rheological flow curves for ECs in high salt. For all points, n=3, and 






Figure 5.10. Frequency sweep for ECs before and after injection into BSS. (A,B) 
PG-MP (+Ta). (C,D) PG-MP (-Ta). (D,E) PRT-MP (+Ta). Crossover frequency 
(G’=G”) indicated by orange dashed line. MP. For all points, n=3, and error bars 
are +/- SD. 
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Figure 5.11. Summary of oscillatory rheology properties at 1 Hz and 1% strain. (A) 
Moduli of ECs injected into BSS. *p<0.05; ** p<0.02; ***p<0.01; ****p<0.001. (B) 
Table of oscillatory rheology properties in high salt (1400 mM) and after injection 






Figure 5.12. Gross tissue response to embolization. Central auricular artery and 
associated branching artery are shown embolized with PG-MP (+Ta). Access site 







Figure 5.13. Histological response to PG-MP +Ta. (A) 1 day with inset (B) showing 
neutrophil migration from patent vessel at left; Neutrophilic inflammation grows 
progressively thicker at 4 days (C), 7 days (D),  and 14 days (E). By 32 days (F), 
vessel is completely obliterated and tantalum has been carried away by 
phagocytes. No signs of recanalization are observed. Scale bars =200 μm. 
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Figure 5.14. Artery embolized with EC at 32 days. (A) H&E stain showing complete 
obliteration of vessel wall with subsiding neutrophilic inflammation. (B) Trichrome 
of same section showing early stage fibrosis within nodule of inflammation (C) High 





Figure 5.15. Histology of PG-P6 +Ta injected into vein at 29 days. (A) H&E stain 
(B) Trichrome, with intact layers of tunica adventitia surrounding embolus (C) High-
magnification inset from B, showing Ta phagocytosis (star) and deposition of 
collagen within the embolus (arrows).  
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RELEASE PROFILE OF ANTIANGIOGENIC EMBOLIC 
COACERVATES LOADED WITH SUNITINIB MALATE 
 
6.1 Abstract 
 Transcatheter embolization procedures are used to obstruct blood flow in a 
blood vessel or vascular bed. Embolization results in localized hypoxia, which 
stimulates the release of a variety of pro-angiogenic factors, most notably vascular 
endothelial growth factor (VEGF). This can eventually lead to revascularization of 
the embolized area. Moreover, after transarterial embolization (TAE) of 
hypervascularized tumors, this hypoxia induced angiogenesis has been linked to 
various measures of poor prognosis, including increased tumor size and eventual 
metastases. Here, previously developed embolic coacervates are augmented to 
release sunitinib malate, an FDA approved antiangiogenic drug. Over the course 
of 14 days, 80% of the loaded drug was released in an in vitro release assay. 
Release of the drug was linear with time, consistent with zero-order release 
kinetics. This study represents a promising first step to developing an embolic 




Hepatocellular carcinoma (HCC) is the second leading cause of cancer 
deaths worldwide, with 782,000 new cases occurring in 2012 [1]. HCC is a 
hypervascular tumor that most often develops in patients with chronic fibrosis 
and/or cirrhosis [2]. Surgical resection or orthotopic liver transplantation, 
depending on liver function, are considered the best option for patients with early 
stage HCC (<3cm) [3, 4]. Unfortunately, HCC is typically undiagnosed until it has 
reached an intermediate to advanced stage where resection or transplantation are 
no longer viable options [4]. Even when resection is done, 55% of patients exhibit 
tumor recurrence within 2 years, most of which are inoperable [3, 5]. In these 
advanced cases, transcatheter embolization has emerged as the primary mode 
therapy for extending survival [6, 7]. HCC is especially amenable to embolization 
because tumor blood supply is derived from the hepatic artery, while blood supply 
to healthy liver tissue is supplied through the portal vein [3].  
While HCC is the most common target for embolotherapy, other 
hypervascular tumors such as renal cell carcinoma, head and neck tumors, and 
colorectal carcinoma can also be treated by embolization. Embolization for tumors 
can be divided into conventional transarterial embolization (TAE) and transarterial 
chemoembolization (TACE). In both procedures, a microcatheter is placed into a 
feeder artery and an embolic agent is delivered into the arterial branches that 
supply the tumor. In TAE, an embolic agent is delivered alone to cause ischemic 
tumor necrosis [8]. TACE differs in that an embolic agent is co-administered with 
a chemotherapeutic agent, often doxorubicin [3]. However, both embolization 
145 
 
methods result in tumor hypoxia which stimulates the release of VEGF, eventually 
leading to revascularization and rebound of the tumor through angiogenesis [6].  
Angiogenesis is the sprouting of new blood vessels from pre-existing 
vessels, usually in response to hypoxia or nutrient deprivation [9]. Activated by a 
variety of proangiogenic signals, endothelial cells detach from perivascular smooth 
muscle cells, sprout along gradients of angiogenic growth factors, coalesce to form 
endothelial tubes, and recruit perivascular cells to form vessels. Finally, 
remodeling and pruning complete the process of maturation [10]. Of relevance in 
embolization therapy, hypoxia is known to stimulate angiogenesis, primarily 
through the transcription factor Hypoxia Inducible Factor 1 (HIF-1). HIF-1 directly 
upregulates transcription of target genes by binding hypoxic responsive elements 
(HREs) within their promoter region. Notably, these include Vascular Endothelial 
Growth Factor (VEGF) and its primary receptor, VEGFR-1 [11]. Through binding 
receptor tyrosine kinases [12], VEGF stimulates endothelial cell mitosis and 
promotes vascular permeability, allowing the extravasation of plasma proteins and 
the formation of a provisional extracellular matrix (ECM), which the endothelial 
cells migrate along. Thus, embolization and chemoembolization procedures, by 
causing hypoxia, can stimulate angiogenesis and revascularization of the 
embolized area. In addition, growing evidence correlates this process with poor 
clinical outcomes [6]. Following TACE, patients have demonstrated significantly 
increased VEGF expression and microvessel density compared to non-embolized 
control groups and pre-embolization baseline levels [13, 14]. Some studies have 
also found that overexpression of VEGF after TACE was associated with later 
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metastases [6, 15, 16]. Depressed VEGF levels following embolization was found 
to be predictive of longer patient survival in another study [17]. 
The potential benefits of antiangiogenic therapy in combination with TAE or 
TACE is well recognized. However, clinical studies regarding the efficacy of such 
combination therapies have exclusively focused on combinations of systemic 
antiangiogenic therapy with embolization and have demonstrated mixed results. 
Phase II clinical trials with the anti-VEGF humanized antibody bevacizumab [6] 
and the receptor tyrosine kinase inhibitors sorafenib [18] and sunitinib [19, 20] in 
combination with TACE and/or TAE have demonstrated decreases in tumor size 
along with increases in mean time to progression and overall survival. However, 
systemic antiangiogenic therapy can have serious side effects [21]. Consequently, 
other clinical trials with sorafenib [22], sunitinib [23], and bevacizumab [6] in 
conjunction with TACE have been stopped because of severe adverse events. 
Thus, localized delivery of an antiangiogenic agent with embolization could 
improve outcomes and diminish safety concerns associated with antiangiogenic 
therapies. 
Previously, our lab has developed embolic agents based upon complex 
coacervates, which, upon injection, harden in situ in response to decreasing ionic 
strength [24]. In early iterations, the embolic coacervates (ECs) were comprised of 
protamine, a cationic polypeptide, and an oligophosphate, phytic acid or sodium 
hexametaphosphate. In Chapter 5, ECs made from a synthetic polyguanidinium 
and MP were produced. These ECs demonstrated superior rheological properties 
compared to the protamine versions, with a lower initial viscosity and much stiffer 
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final form. Furthermore, both protamine and synthetic polymer based ECs have 
generated stable occlusion out to 4 weeks in embolization of the central auricular 
artery of rabbit ears.  
Previously, coacervate-based PECs have been widely used for 
encapsulation and delivery of small molecule drugs [25, 26]. Based upon these 
studies, we hypothesize that passively loading ECs with an antiangiogenic drug 
would allow for localized, sustained delivery into the tissue surrounding the 
embolization site. Here, we report the loading of synthetic ECs with an FDA-
approved antiangiogenic drug, sunitinib malate (Sutent ®; SUN). As a type I 
receptor tyrosine kinase inhibitor (TKI), it inhibits all subgroups of VEGF and PDGF 
receptors [27]. The in vitro release profile of loaded ECs is characterized and 
compared with models of drug release. Based upon these findings, implications of 
future design of antiangiogenic embolic coacervates (AA-ECs) are discussed. 
 
6.3 Results 
6.3.1 Production of EC and SUN Loading 
 Guanylation of 3-aminopropyl methacrylamide (APMA) was used to 
produce the monomer 3-guanidinopropyl methacrylamide (GPMA). For this study, 
a copolymer containing 78 mol% GPMA and 22 mol% methacrylamide (MA) was 
produced by RAFT polymerization, which had a molecular weight of 18 kg/mol (Mw) 
and a polydispersity index (PDI) of 1.04. As in Chapter 5, embolic coacervates 
made using this synthetic guanidinium containing polymer (PG) and 
hexametaphosphate (MP) were produced in 800 mM NaCl to preserve yield 
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(Figure 6.1 A). Previously, a concentrated solution of NaCl was used to raise the 
concentration of monovalent ions within the EC producing an injectable 
formulation. This process is shown in Figure 6.1 B, where a cloudy, viscous 
polyelectrolyte complex made in 800 mM NaCl was converted to a clear, readily 
flowing coacervate with the addition of 4 M NaCl. Here, to simultaneously raise the 
NaCl concentration and load the EC with SUN, a solution of 4 M NaCl and 4 mg/mL 
SUN was added (Figure 6.1 C). The brightly colored SUN was soluble and well-
dispersed in the liquid coacervate. Total loading of SUN was 750 μg/mL. When the 
AA-EC was injected into balanced salt solution (BSS) it qualitatively hardened as 
rapidly and to the same extent as unloaded coacervates, and the SUN remained 
entrapped in the coacervate.  In other words, the high concentration of SUN did 
not drastically affect the material properties or setting reaction of the EC. 
 
6.3.2 Release Profile of AA-ECs 
 In vitro, AA-ECs exhibited sustained release of SUN for 14 days (Figure 
6.2). The release profile was determined by placing 50 μL of EC into a cuvette 
containing 1 mL balanced salt solution (BSS) at pH 6.9. These cuvettes allowed 
for controlling surface area of EC exposed to the solution (0.4 cm2), and thus the 
amount released normalized to surface area was calculated. The BSS release 
solutions were replaced at 1, 3, 6, 9, and 13 days to maintain sink conditions. 
Overall, more SUN was released from ECs without Ta (83%) than from those 
containing Ta (75%) (Figure 6.2 A). However, this difference in release was not 
statistically significant. Because of their similar release profiles, release with Ta will 
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be discussed specifically, but general conclusions are applicable to ECs +/- Ta. 
Over the first 24 h, 4.2 μg of SUN was released (10.6 μg/cm2), which was 11% of 
the total drug loaded (Figure 6.2 B). By day 2, daily release had declined to 1.75 
μg/day, where it remained essentially constant (+/-0.4 μg/day) until 14 days. At 14-
15 days, the system reached a state of depletion, after which no significant release 
occurred. 
 This release profile was unexpected. Drug release from nonswelling 
polymer matrices is typically governed by Fickian diffusion [28, 29]. In this 
scenario, cumulative release is proportional to time1/2, and release is modeled by 
the Higuchi model [30, 31]. However, a zero-order release model was a much 
better fit for the experimental data than the Higuchi model (R2=0.99 vs. 0.94). In 
zero-order kinetics, the cumulative release is linear with time and is represented 
by the equation [30]: 
 
𝑄𝑄𝑡𝑡 = 𝐾𝐾𝐾𝐾 + 𝑄𝑄0 
 
The cumulative drug released (Qt) at time, t, can either be a nominal value 
or a fraction of total drug released (Qt/Q∞).  Q0 represents the initial amount of drug 
in solution (which in this case is none) and/or an initial bolus release. In this case, 
a bolus was observed in the first day. EC (+Ta) was fit to this model in Figure 6.3. 
The intercept (bolus) determined by the model is 1.68 μg (4.2 μg/cm2). This closely 
matches the observed data (Figure 6.2 B), where release on day 1 was more than 
double that seen over the rest of the experiment. Overall, however, this bolus 
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release is small and the release profile can be generally considered zero-order to 
the point of depletion. 
 
6.4 Discussion 
Zero-order release is desirable in drug delivery, as a constant amount of 
drug is delivered regardless of the concentration within the carrier and provides 
predictability. The exact mechanism behind the observed zero-order release 
remains to be fully elucidated. The classical polymeric system for achieving zero-
order release is a reservoir device. This system is comprised of a matrix, which 
contains a low solubility drug, and a rate controlling membrane [28]. This rate-
limiting membrane decouples release from diffusion because diffusion inside the 
matrix is much faster than transport across the membrane. Through interactions 
between the drug and polymer, the phase boundary between the coacervate and 
solution could conceivably function as a rate limiting surface. The guanadinyl 
sidechains of PG, with their cationic charge and Y-aromaticity [32] , provide three 
possible mechanisms of interaction with SUN. First, the GPMA functional group 
could associate with the hydrophobic aromatic rings in SUN through π-π 
interactions. Second, the positive charge could allow guanidinium to interact with 
these same aromatic rings through cation-π bonds, which are among the strongest 
noncovalent bonds [33, 34]. Third, the weak hydration shell above and below the 
guanidinium plane could allow hydrophobic interactions with SUN [35]. Several 
examples of systems with release limited by drug-matrix interactions are found in 
the coacervate and hydrogel literature. However, these systems typically release 
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only a few percent the loaded drug [36-38]. In contrast, ECs released 
approximately 80% of their overall drug payload. This high overall release 
suggests that interactions between PG and SUN are relatively weak and that these 
polymer-drug interactions may not account for this release profile. 
In Chapter 3, it was demonstrated that injecting PRT-MP ECs into 
physiological saline produced a closed porous structure (Figure 3.4). When 
injected into saline, PG-MP ECs exhibit a similar structure, but macroscopically the 
pores are smaller because of faster gelation. Heterogeneous structures, including 
those with pores, have been used to create drug-delivery systems with non-Fickian 
release profiles. In these systems, the release profile depends on the solubility and 
diffusivity of the drug in each of the domains [39]. Under certain circumstances, 
these systems can produce zero-order release [40, 41]. Berg et. al. developed a 
porous polyelectrolyte complex which displayed a linear release profile for two 
model drugs over 20 days [42]. This system utilized a tortuous path of mostly 
connected pore networks to deliver drugs via small surface openings of the pores. 
The pores in ECs could provide channels for diffusion of SUN that allow for faster 
diffusion than through the polymer matrix. However, these pores are mostly closed, 
so it is unlikely that this accounts for the observed zero-order release. 
The most plausible explanation for the observed zero-order release 
involves the pores acting as a reservoir, with the continuous polymer matrix limiting 
diffusion. In a biphasic system, if a drug preferentially partitions into the 
discontinuous phase but is released through the continuous phase, the 
microdomains can serve as a reservoir that keeps drug concentration in the bulk 
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phase nearly constant and produces zero-order release [41]. In ECs, this could 
occur if the drug preferentially partitioned into the in situ formed pores upon setting. 
SUN has a pH and salt concentration dependent aqueous solubility. These closed 
pores are mostly water, but also contain unknown concentrations of salt and 
possibly small amounts of polymer. Conceivably, the solubility of SUN in these 
pores could be up to 25 mg/mL, much higher than the overall drug loading. Under 
this scenario SUN would be released into the media through the concentrated 
polymer phase, but would be mostly excluded from it. The pores would serve as a 
reservoir, keeping the overall concentration in the polymer phase at a pseudo-
steady state and producing zero-order release. This mechanism is depicted in 
Figure 6.4. To generate zero-order release via this mechanism, the fluxes (pore to 
polymer phase and polymer phase to release media) must be similar. This is a 
reasonable assumption, given that the pores and release media are both aqueous 
phases. The reservoir explanation seems the most likely as it considers the entire 
structure of the material, and is consistent with the high fraction of drug payload 
released and the release profile. Future studies on AA-ECs will be designed to 
examine this hypothesis. 
AA-ECs released 80% of their 750 μg/mL payload. While efficacy depends 
on clearance rates and diffusion of the drug, the amount released from 1 mL of 
AA-EC is large compared to the clinically effective plasma range for SUN (50 
ng/mL) [43], suggesting that AA-ECs can likely release sufficient quantities of SUN 
to affect localized angiogenesis. Furthermore, based on the 14 day sustained 
release of SUN from ECs, this system is well suited to limiting ischemia-induced 
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angiogenesis from embolization. After an embolization procedure, hypoxia and 
activation of HIF-1 will occur on a time scale of minutes [44]. The resultant initiation 
of angiogenesis and recruitment of new blood vessels to the tumor occurs through 
the effector functions of RTKs, which are the therapeutic targets for SUN. This 
process normally occurs on the time scale of a few days [45-47].  If new blood 
vessels are not supplied after this period of time, the cells can become dormant or 
even apoptotic through ischemia [48], which suggests that SUN release could 
reduce ischemia induced angiogenesis and slow tumor progression in 
hypervascular tumors. 
However, this in vitro experiment has limitations in predicting results in vivo. 
Given the zero-order release profile, overall drug release is likely to be determined 
by total surface area, with the duration of release being a function of surface to 
volume ratio. Diffusivity of the drug into tissue might also occur at a different rate 
than into saline. Changing the GPMA mol% or molecular weight of the polymer 
alters the properties of the EC and thus might be a tool for modifying and 
maintaining the desired release profile in vivo. 
 
6.5 Conclusion 
 Release of SUN from AA-ECs is linear with time, closely following a zero-
order release profile. The exact mechanism behind this release profile remains a 
topic of future study, but it likely results from closed pores within the set EC 
complex acting as a reservoir system with release occurring through the polymer 
matrix. In these in vitro release studies, AA-ECs delivered 80% of the loaded SUN 
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over the course of 2 weeks. While this release profile would be well suited to 
counteract ischemia induced angiogenesis after embolization procedures, it is only 
a small first step. Further evaluation is needed to gauge release of SUN after an 
in vivo embolization procedure. 
 
6.6 Materials and Methods 
6.6.1 Materials 
N-(3-aminopropyl) methacrylamide hydrochloride (APMA) was obtained 
from Polysciences, Inc. (cat# 21200). 1H-Pyrazole-1-Carboxamidine hydrochloride 
was purchased from Chem-Ipex International (cat# 21678). Methacrylamide (MA; 
L15013) and glacial acetic acid (cat# 36289) were obtained from Alfa Aesar. 4-
methoxyphenol was purchased from TCI chemicals (cat #M0123). 4,4′-Azobis(4-
cyanovaleric acid) (V501; cat# 11590) and azobisisobutyronitrile (AIBN; cat# 
441090) were obtained from Sigma-Aldrich. 4-Cyano-4-(thiobenzoylthio)pentanoic 
acid was purchased from Strem Chemicals (cat# 16-0422). Sunitinib malate (SUN) 
was obtained from Selleckchem (cat#S1042). Sodium acetate was purchased 
from VWR (cat# 0602). USP grade sodium chloride was obtained from MP 
Biosciences (cat# 102892). All solvents were ACS grade or better. Solutions were 
made in ultrapure double deionized water. 
 
6.6.2 Production of Polyguanidinium 
Production of N-(3-methacrylamidopropyl) guanidinium chloride (GPMA) 
and p(GPMA-co-MA) was performed as thoroughly described in Chapter 5. Briefly, 
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GPMA monomer was synthesized by guanylation of N-(3-aminopropyl) 
methacrylamide hydrochloride (APMA) with 1H-pyrazole-1-carboxamidine 
hydrochloride. The purified GPMA product was then copolymerized with 
methacrylamide (MA) in acetate buffer (pH=5.3), using V-501 as the initiator and 
4-Cyano-4-(thiobenzoylthio)pentanoic acid as the chain transfer agent. An 18 
kg/mol (Mw) polymer (PG) was produced with a PDI of 1.04 and 78 mol% GPMA. 
The final product was converted to the hydrochloride salt and purified using 
ultrafiltration. 
 
6.6.3 Production of Anti-Angiogenic 
Embolic Coacervates 
Coacervates of PG and MP were prepared with 1-5 micron Ta powder 
added as a radiocontrast agent (30 wt.% of final coacervate). Aqueous stock 
solutions of PG and MP were made at 100 mg/mL and 200 mg/mL, respectively. 
The pH of both solutions was adjusted to 7.2. Coacervation was achieved by 
sequential addition of DI water, 5M NaCl, MP solution, Ta, and PG solution. In this 
final mixture, PG concentration was fixed at 50 mg/mL; MP concentration was 42 
mg/mL based upon calculated charge densities and a 1:2 charge ratio. Amounts 
of DI water and 5 M salt were adjusted to form an overall NaCl concentration of 
800 mM. Phase separation occurred immediately upon addition of PG, and the 
coacervate was allowed to settle for 12 h before removing the supernatant. 
A stock solution of 4 mg/mL SUN solution in 4 M NaCl was produced by 
dissolving SUN in 1 part DI water at 20 mg/mL and subsequently diluting it with 4 
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parts 5 M NaCl. After removal of the PG-MP supernatant, the SUN+NaCl stock 
was added to raise the salt to 1400 mM and load SUN at 750 μg/mL, forming the 
antiangiogenic embolic coacervate (AA-EC). This supersaturated high-salt 
solution of SUN was used immediately as it would precipitate within an hour. The 
brightly colored SUN appeared soluble and remained well-dispersed in the high-
salt liquid coacervate. 
 
6.6.4 SUN Release 
SUN-containing AA-ECs were produced with and without tantalum. Release 
of SUN was measured by dispensing 50 μL of the AA-ECs (containing 37.5 μg 
SUN) into the bottom of disposable UV-Vis cuvettes and adding 1 mL of BSS 
(pH=6.9). The cuvettes were placed in a temperature controlled incubator at 37°C 
and were shaken at 60 rpm. SUN release was determined at 1, 2, 4, 6, 8, 10, and 
24 h and daily thereafter out to 17 days. To maintain sink conditions, the BSS 
solution was replaced at 1, 3, 6, 9, and 13 days. To measure SUN in the release 
media, absorbance was measured at 431 nm and concentration was determined 
from a standard curve. Cumulative release at each timepoint is reported and is 
normalized by the surface area of the AA-EC exposed to BSS in the cuvette (0.4 







6.6.5 Statistical Analysis 
 Differences in mean overall release (cumulative release at day 17) 
from ECs with and without tantalum was analyzed for statistical significance using 





Figure 6.1. Loading of PG-MP ECs with sunitinib. (A) PG-MP formed in 800 mM 
NaCl. (B) PG-MP EC raised to 1400 mM NaCl. (C) PG-MP EC raised to 1400 mM 






Figure 6.2. Release of sunitinib from PG-MP ECs in BSS. (A) Cumulative release 
profile of SUN. Percent released is out of total SUN loaded. (B) Daily SUN release. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 Conclusion 
 Embolic coacervates (ECs) represent a promising developmental 
liquid embolic agent. These agents, unlike liquid embolics in clinical use, are 
aqueous based systems that eliminate the intraarterial injection of vasotoxic 
organic solvents and exothermically polymerizing monomers. A novel ionic 
strength based setting mechanism is employed which causes a phase transition 
from liquid coacervate to ionic gel. This setting mechanism represents a paradigm 
shift from other approaches to creating aqueous based liquid embolics, 
approaches that are based upon temperature changes or two component mixtures. 
ECs offer a system that can be packaged as a single component preloaded into a 
syringe, avoiding the need for dual lumen catheters. In addition, the non-
temperature based hardening mechanism ensures that the embolic will not begin 
to set until exiting the catheter and allows for small repeated injections of embolic 
agent under fluoroscopic guidance. Radiographic contrast, such as micronized 
tantalum metal, can be suspended in the ECs offering a low-viscosity, shear 
thinning formulation that can be injected through clinically available embolic 
microcatheters. When injected into the relatively low ionic strength environment of 
167 
 
the blood stream, sodium chloride diffuses out of the EC and the polyelectrolyte 
chains begin to interact more strongly, resulting in solidification of the EC. The 
hardening of the ECs upon exposure to low ionic strength environment produces 
a large change in mechanical properties. ECs made with synthetic 
polyguanidinium (PG) and the oligoanion hexametaphosphate (MP) exhibited an 
almost 4 order of magnitude increase in complex shear modulus compared with 
the high salt injectable form. In a percutaneous transcatheter embolization of a 
rabbit kidney, ECs demonstrated the ability to occlude vessels down to the 
capillary level without crossing into venous circulation. Moreover, after 
embolization of the central auricular artery of rabbit ears, the occlusions remained 
stable at 4 weeks. No signs of direct cytotoxicity were observed with the embolic 
agents. However, histological examination revealed neutrophilic inflammation 
which led to destruction of the vessel structure and partial resorption of the 
material. By 4 weeks, this response had begun to resolve and early signs of fibrous 
connective tissue deposition were seen. 
In Chapter 6, ECs were augmented to encapsulate and release the 
antiangiogenic agent Sunitinib malate (SUN). In vitro release experiments 
revealed that ECs released 80% of their SUN payload over the course of 2 weeks.  
A zero-order release profile was observed, indicating that the release was not 
governed by diffusion. It is suspected that this release profile results from closed 
pores within the set EC complex acting as a drug reservoir which keeps 
concentration in the polymer matrix at a pseudo steady state. The high fraction of 
drug released from the EC and the desirable zero order release profile 
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demonstrate the potential of these agents for preventing angiogenic 
revascularization of embolized tissues. 
 
7.2 Future Work 
7.2.1 Long-Term Tissue Biocompatibility 
 The long-term tissue response to PG-MP ECs needs further investigation. 
In embolization of rabbit auricular arteries, PG-MP ECs generated occlusions that 
were stable out to 4 weeks. These ECs incited a severe neutrophilic inflammatory 
response that resulted in destruction of the vessel wall. At 4 weeks, this reaction 
had begun to subside, but some neutrophils were still present. Extensive 
resorption of the material had occurred, and the micronized tantalum was being 
phagocytosed. This phagocytosed tantalum would likely be transported to the 
regional lymph nodes. Another preliminary investigation could examine the use of 
larger tantalum to prevent this transport, although it might incite a more persistent 
inflammatory response. In either case, the tissue response data raises several 
questions that should be addressed in future animal experiments with larger 
sample sizes. First, the long-term fate of the embolus and the tissue surrounding 
the embolization site remains unclear. Early signs of fibrosis suggest that the 
eventual progression might result in the formation of a fibrous scar, but this 
remains speculative. This investigation would also serve to evaluate the 
permanence of the occlusion. Revascularization is seen with virtually all embolic 
agents, but considering the obliteration of vessel structure, it seems unlikely that 
revascularization will proceed by recanalization of the previous vessel lumen. 
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Arterial blood flow to the surrounding tissue would probably be restored via a 
combination of enhancement of extant collateral blood flow and 
neovascularization. A 6-12 month study should more accurately gauge the chronic 
tissue response and eventual fate of the occlusion. 
 
7.2.2 Nonparticulate Contrast Agent 
 Like current liquid embolic agents, the ECs used in this study contain 
micronized tantalum metal powder as a contrast agent. However, these particles 
settle over time and require vigorous mixing before, and sometimes during, a 
procedure. Furthermore, questions remain about the long-term fate of the tantalum 
particles, especially if the embolus is not destined for later surgical resection. An 
ideal solution would be to covalently incorporate contrast directly into the embolic 
agent. The synthetic guanidinium monomer (GPMA) described in this dissertation 
(GPMA) can be copolymerized with a variety of different monomers. Wang et. al. 
has described the synthesis of a tri-iodinated methacrylate monomer [1]. While 
macro chain transfer agents were produced with this monomer, its low solubility 
would need to be overcome to produce random copolymers with GPMA for 
production of ECs. Additionally, the unknown effects of this dense, hydrophobic 
monomer on the properties of the ECs would likely necessitate reformulation. 
Another possible strategy would be to make the EC in a high ionic strength solution 
of sodium iodate (NaI) rather than NaCl. Work by Ghostine et. al. has shown that 
NaI is more effective than NaCl at disrupting interchain ion pairing in polyelectrolyte 
complexes due to hydration effects [2].  Thus, producing an injectable EC would 
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likely require a lower overall ionic strength. However, the replacement of NaCl with 
NaI might affect the safety profile of ECs. While doses >60 mg/kg of NaI are used 
in veterinary medicine (EC would contain <200 mg in a 1 mL injection), the effect 
of I- on the local tissue environment remains a concern with this approach. 
 
7.2.3 Effects of Polymer Characteristics 
 From the literature on ionic strength dependent phase transitions in 
polyelectrolyte complexes, it is well reported that higher molecular weight and 
charge density favor complexation; that is, they decrease the critical salt 
concentration for the solution-coacervate and coacervate-precipitate phase 
transitions [3-6]. From the work done on ECs thus far, this appears to hold true for 
low salt rheological properties. Particularly, the complexes in physiological saline 
become stronger with increasing molecular weight and charge density. This was 
illustrated by the >2 order of magnitude increase in complex modulus in switching 
from the polycation from PRT to PG. However, confounding factors cast 
uncertainty about the magnitude of these effects. In this case, the molecular weight 
was ostensibly modified. While the molar fraction of guanidinium containing 
sidechains was increased from 65% to 80%, the charge density per unit mass was 
the same in both cases. Hydrophobicity is another factor that can drastically affect 
the behavior of PEs [7], and the aliphatic backbone of PG is more hydrophobic 
than the peptide backbone of PG. Furthermore, while PG ECs had stronger 
mechanical properties in physiological saline, they had a lower viscosity at high 
salt. In other words, the shift from PRT to PG made the ECs more salt sensitive, 
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but the reason for this increased salt sensitivity is unclear. 
 The synthetic guanidinium copolymers described in this dissertation provide 
a tool for studying the effects of these characteristics on rheology both in high and 
low salt concentrations. The polymers can easily be made with varying monomer 
feed ratios, and RAFT polymerization provides precise control of the molecular 
weight. While changing the backbone to study hydrophobicity is more difficult, 
GPMA could easily be copolymerized with other monomers to examine this effect. 
Beyond fundamental knowledge about PEC behavior, these studies could guide 
design and optimization of ECs. For example, the degree of distal penetration is 
an important feature of embolic agents, but the amount of penetration desired 
varies with the procedure. An agent that causes more distal penetration will cause 
more ischemia, which is desired in certain situations such as AVMs, but undesired 
in other scenarios such as a small GI hemorrhage [8]. Carugo et. al. has developed 
a microfluidics device with bifurcations and progressively smaller vessels to gauge 
the distal penetration of PVA particles [9]. A similar device could be used to 
evaluate the distal penetration of ECs into smaller vessels. Correlating these 
observations with rheological properties of the embolics in both low and high salt 
could allow for the optimization of EC formulations for specific surgical outcomes. 
 
7.2.4 Future Development of Antiangiogenic ECs 
 The experiments described in Chapter 6 demonstrate feasibility for using 
ECs as combination embolic and drug delivery agents, but these agents need to 
be more thoroughly characterized. Injection force measurements, followed by 
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rheological characterization of these ECs in high and low salt, would be the first 
steps in this process, as these experiments will identify any effects of SUN loading 
on material properties and guide any reformulation of the ECs to accommodate 
these changes. Angiogenesis is a difficult process to replicate using in vitro assays, 
and because SUN is already a clinically proven antiangiogenic agent, these assays 
would be of little value. After the release profile and material properties are fully 
characterized, evaluation in animal models should be pursued. For in vivo 
evaluation of the antiangiogenic ECs, two options exist. Testing the AA-ECs in a 
hypervascular tumor model would allow direct testing of the hypotheses for this 
treatment: AA-ECs will (1) reduce postembolization angiogenesis and (2) slow 
tumor progression in embolization of hypervascular tumors. The rabbit VX2 tumor 
model is virus-induced squamous cell carcinoma which can be rapidly grown in 
rabbit skeletal muscle and transplanted to the liver, where it is commonly used as 
a model of hepatocellular carcinoma. It can be accessed and embolized using 
interventional radiology techniques [10]. Finally, there are well-established 
techniques for semi-quantitatively evaluating angiogenesis in this model [11]. 
However, this model is technically demanding and large numbers of animals would 
be needed to derive statistical significance. For this reason, it may be useful to 
begin in vivo evaluation with a pilot study in simpler model like the corneal 
angiogenesis model, which would allow for more direct measurement of 
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